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Prologue 
In this thesis we explore cancer pain management. During my Master Nutrition and Health 
at the Wageningen University, I gained special interest in improving quality of life in patients 
with cancer. As pain is one of the most common and feared symptoms of cancer I was 
inspired by this study. 
One of the important lessons I learned during my PhD was that performing a study in 
clinical practice is not just applying the research protocol into practice. 
I hope this thesis will encourage active involvement of patients in their own pain 
management and can help to change thinking about cancer pain management. 
“Mijn motivatie om dit proefschrift tot een goed einde te brengen is onder andere geweest de 
pijn die jij hebt moeten doorstaan tijdens de ziekte die je K noemde, omdat je het zo` n naar 
woord vond.” Lieve oma, ik draag dit proefschrift aan jou op. 
Introduction
1
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Introduction
Mrs A is diagnosed with cancer and suffers from pain in her back associated with bone 
metastasis. She is not able to dress herself anymore because of her back pain. She visits the 
outpatient clinic. Mrs A hesitates to talk about her pain with her oncologist, because she fears 
addiction to pain medication and that talking about pain might distract her medical specialist 
form the life prolonging anti- cancer treatment. The oncologist asks Mrs A if she is doing well. 
She answers that she is doing quite well and the oncologist writes “is doing well” in her medical 
record and starts to talk about cancer treatment.
Suffering from cancer pain
In our aging society, cancer prevalence is steadily on the rise. In 2012, the 10-year 
prevalence of cancer in the Netherlands was 454,388, with 101,864  patients newly 
diagnosed; in 2013, the 10-year prevalence was 468,939, with 101,848 patients newly 
diagnosed1. Trends from 1989 to 2011 show an average annual increase in incidence of 
3%2. In 2012, the total number of deaths was 141,000 in the Netherlands of which 43,000 
(31%) died of cancer3. This illustrates the number of patients in an advanced stage of the 
disease, which is associated with increased pain. Pain is one of the most prevalent 
symptoms of patients with cancer4, with a prevalence ranging from 27%5 to 60%6. Pain 
can be caused by the tumour itself, can be related to cancer (e.g. muscle spasm, 
lymphoedema), or to the anticancer treatment7. 
Pain treatment is still inadequate in 31%8 to 65%5 of all patients with cancer, whereas 
adequate pain relief is considered feasible in 71%9 to 86%10 of patients if adequately 
treated. Pain management is essential in all stages of the oncological disease process. 
 Undertreatment of cancer pain is associated with anxiety, depression and sleep 
disturbances11-13; It hampers daily activities14, and therefore affects quality of life in these 
patients. 
 Undertreatment is the result of different patient- and care provider related barriers. 
A key patient-related barrier in cancer pain management is the reluctance of many patients 
to discuss pain with their doctor or to ask for pain medication15. This hesitation has a 
variety of reasons, such as concerns about addiction and fear that reporting pain will 
distract the physician from treating the cancer15. Care providers also experience barriers 
in cancer pain diagnosis. These include ineffective pain communication with patients16 
and inadequate pain assessment17.  
 Pain treatment is inadequate despite the availability of evidence-based clinical practice 
guidelines (CPGs). The Dutch CPG “Pain in patients with cancer”, developed in 2008, is one of 
the most recent guidelines on this subject in Europe18. One of the key recommendations of 
this CPG is assessment and registration of pain using a validated pain assessment tool 
each time the patient visits the outpatient clinic8,18. 
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 Factors associated with the guideline itself, the organization or setting, the professional 
and the patient all effect guideline adherence. A structured implementation strategy is 
necessary to improve cancer pain management26. This comprises many challenges at 
the organisation, patient and caregiver level. In this thesis, challenges at different levels will 
be studied and discussed: Adequacy of cancer pain treatment, cancer pain registration 
by medical oncologists, medical oncologists`  adherence to the guideline, the effects of 
pain monitoring with telemedicine on inadequate cancer pain treatment and active 
involvement of the patient with cancer in their own pain management. 
Pain registration
An overview of the pharmacological history, including a list of medication, the response 
to this medication and possible side effects is important to reflect on prescribed treatment 
and to adjust treatment when needed27. This might improve communication between 
the patient and the physician and facilitates monitoring of pain treatment. 
 To improve accuracy of a patient` s current level of pain, validated quantitative measures 
of pain should be used. Numeric rating scales (NRS) and visual analogue scales (VAS) are 
validated and most commonly used. An NRS asks patients to rate their pain from 0 for no 
pain to 10 for the worst pain imaginable. 
 Although Serlin and colleagues established pain intensity cut-off points already 18 years 
ago, there is still no consensus on how to categorize pain intensity14. Most often, pain is 
categorized as mild pain (NRS 1-4), moderate pain (NRS 5-6), and severe pain (NRS 7-10)14. 
Despite the availability of simple validated pain assessment tools, in 2001, a study showed 
that pain was not systematically assessed and registered in oncology practice.28 The 
authors reported that none of the medical records of patients with pain included 
quantitative documentation. 
 Implementation of guidelines addressing pain assessment has been demonstrated 
to improve pain outcomes29.
Pain Management Index (PMI)
The Pain Management Index (PMI) considers pain treatment to be adequate if there is 
congruence between the patient`s reported level of worst pain and the prescribed 
analgesics30,15. To determine adequacy of analgesic pain treatment, Cleeland`s30 or 
Wards` s Pain Management Index (PMI)15 can be used. Cleelands PMI compares the most 
potent analgesic prescribed with patient`s reported worst pain intensity30. The levels of 
analgesic treatment are scored as 0, no analgesic; 1 a non-opioid analgesic; 2 a weak 
opioid; and 3 a strong opioid. The levels of worst pain are scored as 0, absence of pain; 
1, mild pain; 2, moderate pain; and 3, severe pain. The PMI score is determined by subtracting 
the pain level from the analgesic level and can range from -3 (a patient with severe pain 
receiving no analgesic) to +3( a patient with no pain receiving a strong opioid or equivalent). 
A PMI score between 0 and 3 indicate adequate pain treatment. 
However, publishing a guideline alone is insufficient19; an implementation strategy is also 
needed. This strategy should address patient and physician related barriers in cancer pain 
management. 
What this thesis adds
Pain in patients with cancer has been well studied4-6,8.  However, pain management is 
poorly understood in medical oncology outpatients. To get more insight in cancer pain 
management, in this thesis we explored pain prevalence, pain treatment adequacy, pain- 
related interference with daily activities, pain assessment and pain registration. Exploring 
the problem of cancer pain management is essential to increase awareness. 
 In addition, we monitored patients to assess the effect using the interactive distance 
alert system (MIDAS 4 Cancer Pain) on inadequate cancer pain treatment and discussed the 
active involvement of  patients with cancer in their pain management to provide recommen-
dations for clinical practice.  
Concept of pain 
The international Association for the Study of Pain (IASP) defined pain as: ‘an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage’20.
 Pain can be distinguished into nociceptive and neuropathic pain. Nociceptive pain is 
defined as ‘pain that arises from actual or threatened damage to non-neural tissue and is due to 
the activation of nociceptors’ and neuropathic pain as ‘pain caused by a lesion or disease of the 
somatosensory nervous system’20. Pain is multidimensional including physical, psychosocial 
and existential dimensions. For example psychological distress (depression, anxiety, anger) 
has been shown to be significantly associated with an increased perception of pain21. 
Cancer pain relief 
The aim of adequate pain management is to reduce pain intensity towards an acceptable 
level with minimal side effects22. Often cancer-related pain management initially consists 
of a combination of anti-tumour treatment and pharmacotherapy23. In 1986, The World 
Health Organization (WHO) published the three step analgesic ladder23. This WHO ladder 
describes the following analgesic treatment steps:
step 1 acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs); step 2 weak 
opioids as codeine and tramadol; step 3 strong opioids such as morphine, fentanyl and 
hydromorphone. For optimal pain relief the multidimensional aspects including physical, 
psychological and spiritual aspects of pain should be taken into account. 
The role of clinical practice guidelines 
CPGs can play an important role in improving the quality of care24,25. Developing and 
publishing a guideline is not a guarantee that the guideline will be used26. 
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Patients hear a recorded message on their phone and respond to queries using their keypad. 
SMS-alerts are text messages used to alert health professionals when symptom scores need 
follow-up. Patients will be asked to report pain on an NRS twice daily, once a week, for 12 
weeks. As part of the MIDAS 4 Cancer Pain treatment, an automatic alert (by SMS and email) 
will be sent to the study nurse when a patient reports a pain score of 5 or higher. The study 
nurse then contacts the patient within two hours and advises the patient or adjusts pain 
medication. In addition, the study nurse activates IVR calls and SMS-alerts for the next 
two days to monitor the clinical impact of the advice or medication change.
 IVR-SMS is an example of a telemedicine tool to create a communication network to 
monitor pain. IVR -SMS creates the possibility to monitor pain at home between consultations. 
Although a pain diary can also be used to monitor pain between consultations, with IVR- 
SMS it is possible to act directly, without time delay, on high pain scores and thus shorten 
the period that patients unnecessarily suffer from pain. 
 In previous studies SMS-alerts were used in management of asthma38-40, irritable 
bowel syndrome41, diabetes42 and recurrent pain in children43. 
 A pilot test using IVR-SMS alerts to collect prospective and follow-up data on pain 
intensity in patients with cancer was considered acceptable44. 
 In addition, results from a prospective audit exploring the usefulness of a nurse-led 
telephone intervention for supporting patients with cancer treated with capecitabine, 
suggested that nurse-led telephone follow-up can potentially lead to reduced severity of 
symptoms compared to home care45. 
 These results encouraged us to set up a study to assess the effect of using the interactive 
distance alert system (MIDAS 4 Cancer Pain) to monitor patients to reduce inadequate 
pain management. 
 However, in a recent multicentre RCT with 253 patients with advanced lung cancer 
using IVR and alerts to monitor symptoms with nurse feedback appeared to be no more 
effective in reducing symptom burden than monitoring alone46.
 In 2009 already nine out of ten Dutch inhabitants used a mobile phone47; mobile 
phones are now part of daily life. Therefore, using a mobile phone as a telemedicine tool 
in healthcare seems to be an opportunity48,49. The use of mobile phone SMS-alerts and 
IVR may encourage active involvement of oncology outpatients in their own pain 
management. However, the effect of this intervention on the percentage of patients with 
inadequate cancer pain treatment has never been evaluated. 
Research questions and outline of  the thesis 
In this thesis we monitor patients to assess the effect using telemedicine on the reduction 
of inadequate cancer pain treatment, discuss active involvement of the patient with 
cancer in their own pain management and provide recommendations for current practice. 
The overall objective is to increase awareness and to provide recommendations for clinical 
practice to improve cancer pain management.
The PMI is based on the WHO ladder and is the most frequently used measure for adequate 
pain treatment and is useful for evaluating the quality of analgesic treatment. 
Theoretical background: patient empowerment
In the past 40 years adequacy of pain treatment in patients with cancer has not improved4. 
Today, both healthcare professionals and administrators clearly recognize that patient 
centered care is important31. Patient centered care could be defined as healthcare providers 
share control of consultations, decisions about interventions or the management of health 
problems with patients32. Patient centered care can be the backbone of a strategy to 
improve cancer pain management. 
 To become real partners in their own care, patients need to be empowered. Since 1988, 
patient empowerment has gained more attention in healthcare33. 
The European Network on Patient Empowerment (ENOPE 2012) defined patient empowerment 
as ‘a process to help people gain control, which includes people taking initiative, solving 
problems, and making decisions’34. It has been highlighted as central to success in pain 
management35. An empowered patient probably self-manages his/her cancer pain to a 
larger extent than a non-empowered patient.
 Telemedicine can support caregivers and patients to achieve patient centered care, 
because it might encourage patients to become a partner in their own pain management. 
Monitoring pain with telemedicine
E-health, such as telemedicine, describes a range of information and communication 
technologies that are used to provide healthcare36.
 Telemedicine is defined as ‘a subset of telehealth, that uses communication networks 
for delivery of healthcare services and medical education from one geographical location 
to another, primarily to address challenges like uneven distribution and shortage of infra-
structural and human resources’36.
 Weiner et al. estimated that if information technology and e-health would be fully 
implemented in 30% of community-based physician`s offices, the healthcare demand for 
US physicians would be reduced with 4-9%37. However, it is unknown whether and how 
this will change quality of care, and it is unknown whether this is also true for the 
Netherlands, with a different culture and health care system. 
Rationale for use of IVR-SMS to monitor pain 
Interactive Voice Response (IVR) with Short Message Service (SMS) alerts allows patients 
to communicate with their healthcare professionals outside the consultation room. 
We will monitor patients to assess the effect using the interactive distance alert system 
(MIDAS 4 Cancer Pain) on the reduction of inadequate cancer pain treatment using 
IVR and SMS-alerts. 
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The scope of the problem 
The following research questions are addressed: 
1. What is the prevalence of pain and its interference with daily activities in 
medical oncology outpatients? Is pain treatment adequate in the medical 
oncology outpatient clinic? In chapter 2 we describe a cross-sectional study in seven 
medical oncology outpatient clinics in the south-eastern part of the Netherlands to 
assess pain prevalence, pain intensity, its interference with daily activities and the 
adequacy of analgesic pain treatment. 
2. How is pain in patients with cancer registered in medical records by oncologists? 
In chapter 3 we report on a multicentre study in six Dutch hospitals with retrospective 
analysis of medical records of 380 outpatients with cancer to explore pain registration. 
3. Adhere oncologists to the recommendations of the Dutch clinical practice 
guideline pain in patients with cancer? In chapter 4 we describe the results of a 
case-vignette study to assess medical oncologists`  reported adherence to evidence- 
based guidelines in cancer pain management. 
How to improve cancer pain management in the outpatient clinic
The following research questions are addressed: 
4. Is IVR-SMS suitable as tool for systematic pain monitoring in patients with 
cancer? In chapter 5 we describe the rationale, design and implementation protocol 
of the Dutch clinical guideline pain in patients with cancer. 
5. Is patient monitoring using interactive distance alert system (MIDAS 4 Cancer 
Pain) more effective in reducing the percentage of patients with inadequate 
cancer pain treatment than usual care? In chapter 6 we report on the results of a 
cluster randomised trial (RCT). We monitored patients to assess the effect using the 
interactive distance alert system (MIDAS 4 Cancer Pain) on the reduction of the 
percentage of patients with  inadequate cancer pain treatment.
6. How to promote active patient participation in cancer pain management? In 
chapter 7 we describe an integrative literature review evaluating papers discussing 
empowerment or related concepts in relation to pain management in patients with 
cancer. We propose a conceptual model to empower patients in controlling cancer 
pain. 
In chapter 8 the results were discussed. 
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Pain and its interference with daily activities  
in medical oncology outpatients
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Background
Pain is one of the most prevalent symptoms in patients with cancer1 and appeared to 
interfere with daily activities in patients with advanced cancer.2 In patients with cancer 
visiting outpatient clinics, pain prevalence ranged from 27% 3 to 60%4. Additionally, 19% 
to 39% of patients with cancer suffered from neuropathic pain, caused by the tumour, the 
operation or the treatment5. Adequate pain relief in 71%6 to 86%7 of cancer pain is 
considered feasible. As inadequate pain treatment ranged from 31%8 to 65%3 in patients 
with cancer, pain is still undertreated.
 Undertreatment is the result of different patient and care provider related barriers. A key 
patient related barrier in pain management is the reluctance of many patients to discuss 
pain with their doctor or to ask for pain medication9. This hesitation has a variety of 
reasons, such as concerns about addiction and fear that reporting pain will distract the 
physician from the treatment of their cancer9. Care providers also experience barriers in 
cancer pain diagnosis. These include ineffective pain communication with patients10  and 
inadequate pain assessment.11 This underassessment and undertreatment of cancer pain 
influences the quality of life of these patients.
 Moreover, cancer pain is associated with anxiety, depression and sleep disturbances12-14. 
It hampers daily activities15,  which also affects the quality of life. Putting it in day-to-day 
terms: if you are unable to work because you experience severe pain when moving your 
arm, this obviously reduces the quality of your life.
 Pain related interference with daily activities has been well studied16-19. However, pain 
management patterns are poorly understood in medical oncology outpatients. 
 To get more insight in these patterns, we explored pain prevalence and intensity, 
analgesic pain treatment, neuropathic pain characteristics, breakthrough pain, pain related 
interference with daily activities and predictors of pain in outpatients with cancer. 
 The primary objective was to assess pain prevalence, pain intensity and its interference 
with daily activities in medical oncology outpatients. The secondary objectives were the 
adequacy of analgesic pain treatment and to identify independent predictors for moderate 
to severe pain.
Methods
Patients and procedures
A cross-sectional survey study was performed. Patients with cancer, visiting the medical 
oncology outpatient clinic of one of seven Dutch regional hospitals, were invited to participate. 
 Patients were eligible to participate if they had been diagnosed with cancer and were 
18 years or older. Exclusion criteria were severe cognitive dysfunction or inability to 
understand or read the Dutch language. 
Abstract
Background. Pain prevalence at various stages of cancer ranged from 27% to 60% for 
outpatients. Yet, how pain is managed in this patient group is poorly understood. The 
primary objective was to assess pain prevalence, pain intensity and its interference with 
daily activities in medical oncology outpatients. The secondary objectives were the 
adequacy of analgesic pain treatment and to identify independent predictors for 
moderate to severe pain. Methods. Four hundred twenty-eight medical oncology 
outpatients were assigned to the study. Pain prevalence and interference of pain with 
daily activities were assessed using the Brief Pain Inventory. Adequacy of analgesic 
treatment was determined by calculating the Pain Management Index (PMI). Descriptive 
statistics, non-parametric tests and logistic regression analysis were conducted. Results. 
More than one third of all participants reported pain (39%). Eighty-three patients (20% of 
all) had moderate to severe pain (NRS 5 -10). Analgesic treatment was inadequate in more 
than half of the patients with pain (62%). Interference of pain with daily activities increased 
with increased intensity, yet even 10%-33% of patients suffering mild pain reported high 
interference with daily activities. High current pain intensity and high interference with 
general daily activities predicted moderate to severe pain. Conclusion. Pain remains a 
significant problem in medical oncology outpatients and pain is often insufficiently 
managed. Patients with a high pain intensity were more at risk to experience pain related 
interference with daily activities, but even quite some patients suffering mild pain 
experienced this. As adequate pain relief for up to 86% of the patients with cancer should 
be feasible, pain in medical oncology outpatients is still undertreated.  Interference of pain 
with daily activities and predictors of pain should be taken into account to facilitate cancer 
pain management.
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DN4
Neuropathic pain was, as accepted by the IASP, defined as “pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system” 26,27. We assessed 
the presence of characteristics of neuropathic pain (NP) by using the seven-item DN4-
interview28. The complete DN4 has been linguistically validated in Dutch29. The DN4- 
interview includes pain descriptors namely burning, painful cold, electric shocks and 
associated abnormal sensations, tingling, pins and needles, numbness and itching. Each 
positive answer is assigned a score of 1. 
 If at least three out of seven characteristics of neuropathic pain are answered with 
yes, pain includes neuropathic characteristics and this might be an indication that 
neuropathic pain is present.
Additional data from medical records
Of those patients participating in 2012, additional data were retrieved from their medical 
records, namely disease characteristics, prescribed analgesics and treatment intention.
Statistical analysis
Descriptive statistics were conducted with SPSS version 20. Outcome variables were pain 
prevalence, pain intensity and interference of pain with daily activities. Worst, least, 
average and current pain levels were obtained. A numeric rating scale (NRS) from 1-4 was 
categorized as mild, 5-6 as moderate and 7-10 as severe pain30. This categorization was 
used because the present study was based on the principles of the Dutch clinical practice 
guideline (CPG) on cancer pain, being one of the most recent and best CPGs in Europe30,31.
Disease groups were categorized as 1a: patients treated with curative intention more than 
6 months ago; 1b: patients treated with curative intention less than 6 months ago; 2: 
patients with palliative anti-cancer treatment; 3: patients for whom anti-cancer treatment 
was not or no longer feasible and patients with palliative treatment more than 6 months 
ago (1). Differences in proportions were tested with Chi-square test or Fisher’s exact test. 
Reported p-values are two-tailed and considered significant at the p <0.05 level. Kruskal- 
Wallis tests were conducted to compare median pain scores and median pain related 
interference with daily activities scores.
 Additionally, multiple regression analyses were conducted to determine the extent to 
which pain intensity rating (least, worst, average and current) was related to interference 
of pain with daily activities once other ratings were controlled. Mean interference of the 
six daily activities was the dependent variable and each pain intensity rating (least, worst, 
average and current) was added as a predictor of interference in the second step of the 
regression analysis after the other three were entered in the first step (methodology 
adapted from Chi et al)31.
 Finally, univariable and multivariable logistic regression analysis were conducted with 
the presence of moderate to severe pain (yes/no) as dependent variable. 
In each hospital, in two periods of five consecutive working days, one period in 2011 and 
one in 2012, all patients visiting the medical oncology outpatient clinic were asked to 
participate. 
Data collection
Patients were asked to complete the questionnaire during their stay at the outpatient clinic. 
A medical student helped them to fill in the questionnaire. The questionnaire consisted of 
the Brief Pain Inventory (BPI), Douleur Neuropathic 4 (DN4) interview, a question about 
breakthrough pain, intake of medication in the last 24 hours, demographics and medical 
data. 
 Besides, of those patients that took part in 2012, additional information was extracted 
from their medical records after they had provided their informed consent. 
Brief Pain Inventory (BPI)
The BPI was used to assess pain prevalence and interference with daily activities21. This BPI 
is linguistically validated in many languages, including Dutch21. The BPI consists of seven 
questions with 15 items and has 11-point Numeric Rating Scales (NRS) of 0 (no pain) to 10 
(worst pain imaginable), in which patients are asked to rate their mean pain over the last 
24 hours. Additionally, the BPI was used to ask for interference of pain with daily activities 
over the last 24 hours (mood, walking ability, normal work, relationships, sleep and 
enjoyment of life).
Pain management index (PMI)
To determine the adequacy of analgesic pain treatment, Cleeland’s22  and Ward’s PMI9 
were used. Based on the WHO pain ladder24. the PMI is the most frequently used measure 
for adequate pain treatment and is useful for evaluating the quality of analgesic care in 
large sample cases25.  Ward’s PMI was calculated for participants when prescribed 
analgesics were not described in the medical record9,23. Pain treatment is considered 
adequate if there is a congruence between the patient`s reported level of worst pain and 
the prescribed analgesics25. Cleeland’s PMI compares the most potent analgesic prescribed 
with the patient’s reported worst pain on the BPI22. Ward’s PMI compares the most potent 
analgesic drug therapy actually used by the patient with his worst pain1,9. 
In both variations of the PMI, the levels of analgesic drug therapy are scored as 0, no 
analgesic; 1, a non-opioid analgesic; 2, a weak opioid  and 3, a strong opioid. Absence of 
pain is defined as 0, mild pain as 1, moderate pain as 2 and severe pain as 39,22. The PMI can 
be determined by subtracting the pain level from the analgesic level. The outcome ranges 
from -3 (a patient with severe pain receiving no analgesic drug) to +3 (a patient with no 
pain receiving a strong opioid or equivalent). Negative scores indicate inadequate pain 
treatment, whereas scores of 0 or higher represent adequate pain treatment9,22.
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The following independent variables were examined: age, gender, education, cancer type 
and disease group, current pain, metastasis, more than 5 years after diagnosis (yes/no), 
and interference with daily activities. Criterion to add a variable into the multivariable 
logistic regression analysis was p<0·10. Moreover, sub-analysis was conducted for gender 
as gender might be a potential confounder for the effect of tumour type on the prevalence 
of moderate to severe pain. All values given are worst pain values, unless otherwise stated. 
Pain intensity values are given as median with the inter quartile range (IQR).
Results 
Of 629 invited patients, 428 (68%) completed the questionnaire. Median age of the 
participants was 67 (58-74). For characteristics of patients see table 1. Nonparticipants 
were patients who had no time to participate because of another appointment, being too 
ill or too tired to participate or patients who said that this would be too confrontational.
Pain prevalence
One hundred and sixty-seven patients (39%) reported pain in the last 24 hours and 36 (8%) 
experienced breakthrough pain. Table 1 shows that pain prevalence appeared higher in 
patients with metastasis than in patients without (p=0.022). A subgroup of 231 patients 
completed the DN4-interview. Fifty-three of them (23%) answered yes for at least 3 out of 
seven characteristics of neuropathic pain. 
Pain intensity
Pain intensity was obtained for worst, least, average and current pain. Forty-three patients 
out of 167 patients in pain (26%) rated their worst pain as moderate and 40 patients (24%) 
as severe. This means that 83 patients out of all 428 patients (20%) had moderate to severe 
pain.
 Patients experienced a median worst pain of 4.0 (IQR 2.0-6.0), least pain of 2.0 (IQR 
0.0-4.0), average pain of 4.0 (IQR 2.0-5.0) and current pain of 2.0 (IQR 1.0-5.0).
 Table 2 shows median pain intensities in relation to demographics of patients with 
pain. Median pain intensity was higher in women than in men for worst, average and 
current pain (p=0.015; p=0.006; p=0.005). Additionally, table 2 shows that median worst 
pain intensity was higher in disease group 3 than in the other disease groups (p=0.003) 
(n=7). 
Patients with metastasis had an increased risk of pain (P=0.025), but did not have an 
increased risk for higher pain intensity than patients without metastasis. Finally, there were 
no significant differences in mean scores per pain intensity category between different 
tumour types and presence of metastasis.
Table 1  Demographic characteristics of patients (N=428)
Characteristics All  
(N=428)
With pain
(N=167)
Without pain 
(N=261)
N N (%) N (%)
Gender 
Men 177 64 (36.2) 113 (63.8)
Women 251 103 (41.0) 148 (59.0)
Age groups in years
< 45 21 9    (43.0) 12 (57.1)
45-60 97 45 (46.4) 52 (53.6)
60-75 216 81 (37.5) 135 (62.5)
≥ 75 93 31 (33.3) 62 (66.7)
Unknown 1 1 (100.0) 0 (0.0)
Education level
Secondary school or less 117 41 (35.0) 76 (65.0)
Lower vocational education 97 37 (38.1) 60 (61.9)
Middle vocational education 128 52 (40.6) 76 (59.3)
Higher vocational education or higher 84 36 (43.0) 48 (57.1)
Unknown 2 1 (50.0) 1 (50.0)
Primary cancer type 
Gastrointestinal 123 47 (38.2) 76 (61.8)
Urogenital 59 25 (42.4) 34 (57.6)
Breast 153 68 (44.4) 85 (55.6)
Lymphatic-hematological 67 18 (26.9) 49 (73.1)
Other (lung, skin, glands, bone) 21 7 (33.3) 14 (66.7)
Unknown 5 2 (40.0) 3 (60.0)
Presence of metastasesa
Yes 222 98 (44.1) 124 (55.9)
No 203 67 (33.0) 136 (67.0)
Unknown 3 2 (66.7) 1 (33.3)
Period with cancer in years
≤ 1 184 70 (38.0) 114 (62.0)
2 - 5 124 46 (37.1) 78 (62.9)
≥5 118 51 (43.2) 65 (55.1)
Unknown 2    0  (0.0) 2 (100.0)
Disease groupb
1a 11 2 (18.2) 9 (81.8)
1b 58 26 (44.8) 32 (55.2)
2 93 46 (49.5) 47 (50.1)
3 18 7 (39.0) 11 (61.1)
Unknownc 197 65 (38.9) 132 (50.6)
a chi-square or fishers exact test p<0.05 (2-sided); b 1a, patients who had been treated with curative intent, last 
treatment more than 6 months ago; 1b, patients receiving anti-cancer treatment with curative intention or last 
treatment less than 6 months ago; 2, patients who were receiving palliative anti-cancer treatment; 3, patients 
for whom anti-cancer treatment was not or no longer feasible and patients with palliative treatment more than 
6 months ago.1 C obtained from medical records, these data were only available for a subgroup of 231 participants. 
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Table 2   Median and IQR of pain intensity (NRS) in the last 24 hours for different  
demographic characteristics of patients with pain (N=167)
Characteristics N Worst pain in last 24 h Least pain in last 24 h Average pain in last 24 h Current pain in last 24 h
Med (IQR) p-value Med (IQR) p-value Med (IQR) p-value Med (IQR) p-value
Gender 0.015 0.119 0.006 0.005
Men  64 3.5  (2.0-6.0) 1.5 (0.0-3.0) 3.0 (2.0-4.8) 2.0 (1.0-3.0)
Women 103 5.0  (3.0-7.0) 2.0 (0.0-5.0) 4.0 (2.8-6.0) 3.0 (1.0-6.0)
Age groups (years) 0.324 0.988 0.876 0.776
< 45 9 3.0 (2.5-5.0) 2.0 (0.0-4.0) 4.0 (2.0-6.0) 2.0 (1.0-3.5)
45-60 44 4.0 (3.0-6.0) 2.0 (1.0-3.0) 4.0 (2.0-5.0) 3.0 (1.0-5.0)
60-75 81 4.0 (2.0-6.0) 2.0 (0.0-4.0) 3.0 (2.0-5.0) 2.0 (0.5-5.0)
≥ 75 31 5.0 (3.0-7.0) 2.0 (0.0-4.0) 4.0 (2.0-5.0) 2.0 (1.0-6.0)
Education level 0.341 0.259 0.511 0.553
Secondary school or less 41 5.0 (2.0-7.0) 2.0 (1.0-5.0) 4.0 (2.0-6.0) 5.0 (1.0-6.0)
Lower vocational 37 4.0 (3.0-7.0) 2.0 (1.0-4.0) 3.0 (2.0-5.0) 3.0 (1.0-5.0)
Middle vocational 51 4.0 (2.0-5.8) 1.5 (0.0-3.8) 3.0 (2.0-5.0) 2.0 (1.0-4.8)
Higher vocational or higher 36 5.0 (3.0-6.0) 1.5 (0.0-3.0) 4.0 (2.0-5.8) 2.0 (1.0-6.0)
Primary cancer type 0.835 0.333 0.654 0.711
Gastrointestinal 47 5.0 (2.0-7.0) 2.0 (0.0-4.0) 3.0 (2.0-5.0) 2.0 (1.0-5.0)
Urogenital 24 4.0 (2.0-5.0) 1.0 (0.0-3.0) 3.5 (2.0-5.0) 2.0 (0.0-5.0)
Breast 68 5.0 (3.0-6.8) 2.0 (0.0-5.0) 4.0 (2.0-6.0) 3.0 (1.0-6.0)
Lymphatic-haematological 18 4.0 (2.8-6.0) 2.0 (0.8-4.0) 3.5 (2.0-6.0) 3.0 (1.0-6.0)
Other (lung, skin, glands) 7 3.0 (3.0-6.0) 2.0 (1.0-3.0) 3.0 (3.0-4.0) 3.0 (1.0-3.0)
Presence of metastases 0.491 0.824 0.552 0.781
Yes 98 5.0 (0.0-4.3) 2.0 (2.0-5.0) 4.0 (1.0-5.0) 2.0 (1.6-5.0)
No 67 4.0 (3.0-6.0) 2.0 (0.0-3.0) 4.0 (2.0-5.0) 3.0 (1.0-5.0)
Period with cancer (years) 0.419 0.976 0.468 0.805
≤ 1 70 4.0 (2.0-6.0) 2.0 (0.0-4.0) 3.0 (2.0-5.0) 2.0 (1.0-5.0)
2 – 5 47 4.0 (3.0-6.0) 2.0 (0.0-3.0) 4.0 (3.0-5.0) 3.0 (1.0-5.0)
≥5 49 5.0 (2.0-7.0) 2.0 (0.0-4.3) 4.0 (2.0-6.0) 2.5 (0.8-6.0)
Disease groupa 0.022 0.318 0.313 0.355
 1a 2 5.0 (4.0-6.0) 1.0 (0.0-2.0) 4.5 (3.0-6.0) 3.0 (0.0-6.0)
 1b 26 3.0 (2.0-5.3) 1.5 (0.0-4.3) 3.0 (2.0-5.0) 1.5 (1.0-5.0)
 2 46 3.5 (2.0-5.0) 1.0 (0.0-2.3) 3.0 (2.0-5.0) 2.0 (0.0-3.3)
 3 7 7.0 (5.0-9.0) 3.0 (2.0-4.0) 4.0 (3.0-7.0) 3.0 (2.0-7.0)
p= p-value, IQR= Inter Quartile Range, NRS= Numeric rating Scale. Note: the bold values are reaching significance 
with Kruskal- Wallis tests at p<0.05 (2-sided); a Adapted  from van den Beuken et. al. 20071 : see method section 
statistical analysis. 
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Pain related interference with daily activities
Figure 1 shows interference with daily activities per pain intensity category. One patient 
did not respond to the questions on interference with daily activities and was therefore 
excluded from this part of the analysis (n=166). One hundred and forty-eight out of 166 
patients with pain (89%) experienced interference of pain with one or more daily activities. 
The overall median interference of pain with daily activities of patients with pain was 2.6 
(IQR 0.8-5.0). Five percent of patients without pain reported interference with daily 
activities (see figure 1a).
 Patients who rated their worst pain in the last 24 hours as mild (n=84) had an overall 
median interference of pain with daily activities of 1.1 (IQR 0.2-3.3). This figure is 3.1 (IQR 
2.0-4.9) for patients with moderate pain (n=42) and 4.9 (IQR 2.7-5.8) for patients with severe 
pain (n=40) (p<0.0001).
 However, prevalence of interference with daily activities ≥ 5 in patients with mild pain 
ranged from eight out of 84 (10%) to 27 out of 84 (33%) over the various activities. Even up 
to eight out of 42 patients (19%) with a pain intensity of NRS 1-2 reported interference with 
daily activities ≥ 5 for work (including household). Most often pain negatively interfered 
with work/household and general activity.
 Figure 1 also shows that median interference with daily activities was higher in 
patients with moderate pain than in those with mild pain for all activities (p<0.05) except 
for sleep (p=0.125). 
 Severe pain interfered significantly more than moderate pain with sleep and general 
activity. Severe pain interfered significantly more with each daily activity than mild pain 
(P<0.05). Additionally, figure 1 shows higher interference with daily activities in patients 
with high pain intensity. Negative interference with enjoyment, work, mood, sleep, and 
general activities with an NRS score of 7-10 was more common regarding severe pain than 
regarding mild and moderate pain. 
 Worst pain contributed most to interference with daily activities (R2=0.014; F 16.15; 
p=0.00). Worst pain contributed more to interference with daily activities than current 
pain (R2=0.008; F 9.37; p=0.002). 
Evaluation of analgesic pain treatment
Analgesic pain treatment in relation to pain severity is summarized in figure 2. Strong 
opioids were used by one out of eight patients with mild pain and moderate pain, whereas 
in patients with severe pain one out of three strong opioids were used. Of patients with 
moderate to severe pain 28.6% were not treated with analgesics and 42.9% with a non- 
opioid drug.
 Due to unclear recording of  prescribed analgesics, data of 22 patients could not be 
included in calculating Cleeland’s PMI. For these patients Ward’s PMI was calculated. One 
hundred and three out of 167 patients in pain (62%) were inadequately treated according 
to the PMI. Patient characteristics did not influence adequacy of analgesic treatment. 
Figure 1   Pain related interference with daily activities of patients with cancer by pain 
intensity category (%) 
Note: Pain intensity categories used were adapted  from the Dutch guideline: pain in patients with  cancer (28). *includes 
household; ** Data was missing of one pateint (patient was excluded from figures); NRS= Numeric Rating Scale.   
1a  Patients without pain (NRS 0) (N=260)                    
1b  Patients with mild pain (NRS 1-4) (N=84) 
1c  Patients with moderate pain (NRS 5-6) (N=42)** 
1d  Patients with severe pain (NRS 7-10) (N=40)  
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However, patients with breast cancer and pain were more often inadequately treated than 
patients with other tumour types (p=0.001).  Forty-seven percent of patients who answered 
yes for at least 3 neuropathic pain characteristics out of seven were inadequately treated 
for their pain compared to 20% of patients who answered  yes for less than 3 out of seven 
neuropathic pain characteristics (p=0.00). 
Logistic regression 
Gender, having a lymphatic-haematological tumour, presence of metastasis, current pain 
and interference with daily activities were related to moderate to severe pain, whereas 
education level, tumour type, more than five years since diagnosed with cancer and 
disease group were not (see table 3). Multiple regression analysis revealed that current 
pain (OR 2.96, CI 2.28-3.85), interference with daily activities for general activity (OR 1.14, CI 
1.14-1.52), and having a lymphatic-haematological tumour (OR 0.11, CI 0.02-0.54) were 
independently related to moderate to severe pain.
 Multiple regression analysis for men revealed that current pain (OR 3.3, CI 2.19-4.96) 
and interference with sleep (OR 1.43, CI 1.14-1.80) were related to moderate to severe pain. 
Multiple regression analysis for women revealed that current pain (OR 3.2, CI 2.40-4.34) 
and interference with general daily activities (OR 1.43, CI 1.14-1.80) were related to moderate 
to severe pain.
Figure 2   Analgesic pain treatment in relation to pain severity*
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Table 3   Odds ratios and 95% CI of the probability of moderate to severe pain (NRS 5-10) 
in patients with cancer
Characteristics N Univariable regres-
sion
Adjusted 
OR (95% CI) OR  (95% CI)b
Gender
Men 177 1.00 (reference) -
Women 251 1.79 (1.07-2.99) a Not in model
Age  (years) 427 1.00 (0.98-1.03) -
Education level
Secondary school or less 177 1.00 (reference) -
Lower vocational education 97 0.87 (0.48-1.57) -
Middle vocational education 128 0.60 (0.34-1.07) -
Higher vocational education or higher 84 1.42 (0.80-2.52) -
Primary cancer type 
Gastrointestinal 123 0.84 (0.48-1.47) -
Urogenital 59 0.91 (0.44-1.90) -
Breast 153 1.00 (reference) -
Lymphatic-haematological 67 0.37 (0.15-0.89)a 0.11 (0.02-0.54)a
Other ( lung, skin, glands, bone) 21 0.43 (0.10-1.89) -
Presence of metastases 425 1.76 (1.07-2.90)a Not in model
More than 5 years diagnosed 426 1.39 (0.82-2.33) -
Disease groupc
1a 11 0.41 (0.05-3.33) -
1b 58 0.71 (0.31-1.64) -
2 93 1.00 (reference) -
3 18 2.39 (0.83-6.92) -
Current pain 428 3.26 (2.57-4.13)a 2.96 (2.28-3.85)a
Daily activity interferenced
Enjoyment 427 1.64 (1.47-1.83)a Not in model
Work (includes household) 427 1.53 (1.41-1.67)a Not in model
Mood 427 1.70 (1.50-1.90)a Not in model
Walking 427 1.58 (1.43-1.74)a Not in model
Relations 427 1.79 (1.54-2.10)a Not in model
Sleep 427 1.53 (1.39-1.70)a Not in model
General 427 1.70 (1.53-1.90)a 1.14 (1.14-1.52)a
NRS= Numeric Rating Scale; 95% CI= 95% confidence interval; OR= odds ratio. a p≤0.10. b Stepwise univariable 
regression analysis. Criterion to add a variable was p≤0.10. cAdapted from van den Beuken et. al. 20071: disease 
group 1a, patients who had been treated with curative intent, last treatment more than 6 months ago; 1b patients 
receiving anti-cancer treatment with curative intention or last treatment less than 6 months ago; 2, patients who 
were receiving palliative anti-cancer treatment; 3, patients for whom anti-cancer treatment was not or no longer 
feasible and patients with palliative treatment more than 6 months ago: Obtained from medical records, these data 
were only available for a subgroup of 231 participants. d Data of one patients was missing. 
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Our data confirms these findings. This indicates that ratings of worst pain in the last 
24 hours, rather than current pain, might improve insight in overall experience of pain and 
its impact on interference with daily activities in medical oncology outpatients34. This 
might guide the choice of recall period for outpatients with cancer for future studies. 
 Previous literature stated that patients with a pain intensity <5 are adequately treated 
and that mild pain intensity hardly interferes with daily activities15,30.
 However, the present study shows that some patients with mild pain (NRS 1-4) and 
even some patients with an NRS of 1-2 do experience moderate to high interference with 
daily activities, as also described by Wu et al35. 
 Although Serlin and colleagues established cut-off points for pain intensity based on 
its interference with daily activities 18 years ago15, there is still no consensus on how to 
categorize pain intensity. Often pain is categorized as mild pain (NRS 1-4), moderate pain 
(5-6) and severe pain (7-10)15,30.  
 As a complicating but important factor in this discussion on cut-off points, we 
suggest including interference with daily activities as an additional factor to determine, in 
combination with pain intensity, whether a patient with cancer and pain needs treatment. 
Little is published on predictors of the prevalence of moderate to severe pain. In our study, 
women were more at risk for moderate to severe pain than men. Some studies confirm 
this finding36, others do not1. Additionally, in our study patients with metastasis were more 
at risk for moderate to severe pain, which confirms a previous finding that patients with 
more advanced disease had higher pain intensities20. None of the previous studies 
explored interference with daily activities and current pain as possible related variables for 
moderate to severe worst pain in the last 24 hours. 
 Unfortunately, we were not able to obtain characteristics from the 32% non-partici-
pants, as informed consent would have been needed to obtain information from medical 
records. 
 The present study was based on the recommendations in the Dutch CPG “Pain in 
patients with cancer”30  which is one of the most recent cancer pain guidelines in Europe. 
In a comparative study of European CPGs on pain management in patients with cancer 
this Dutch CPG appeared to have followed a good development process31.  
 So far, it is not known whether this CPG has already improved adequate pain treatment 
in the Netherlands37.  The present study contributes to awareness on pain prevalence, pain 
treatment adequacy and interference of pain with daily activities. It is an essential step in 
improving cancer pain management.
Discussion
The present study shows that more than one third of all participants, i.e. patients with 
cancer visiting a medical oncology outpatient clinic, reported pain. Half of those in pain 
had inadequate analgesics treatment. Additionally, high pain intensity strongly interfered 
with daily activities and even 10%-33% of patients with mild pain, which pain level is not 
usually treated with opioids, experienced moderate to severe interference with daily 
activities. High current pain intensity and high interference with general daily activities 
were related to moderate to severe pain.  
 Subsequently, pain prevalence appeared higher in patients with metastasis than 
without and  patients with breast cancer and pain were more often inadequately treated 
than patients with other tumour types. Positive predictors for moderate to severe worst 
pain in the last 24 hours were current pain and interference with general daily activity 
while having a lymphatic-haematological tumour was a negative predictor. 
 Earlier studies in Europe found pain prevalence at various stages of cancer from 27%3 
to 60%4 for patients visiting outpatient clinics with cancer. Inadequate pain treatment 
ranged from 31%8 to 65%3 in patients with cancer. The prevalence rates in the present 
study fall within the range found in previous studies. As adequate pain relief for up to 86% of 
patients with cancer is considered feasible, pain in patients with cancer is still undertreated7.
 In previous studies, prevalence rates of neuropathic pain in patients with severe 
cancer pain ranged from 34%-40%5. In our study, in which also patients without pain 
participated, neuropathic pain prevalence rate was less. Additionally, our study shows that 
patients who answered yes for at least 3 NP characteristics were more often inadequately 
treated for their pain than patients without or with less NP characteristics (p=0.00). 
 As neuropathic pain is generally treated with opioids and adjuvants and is relatively 
opioid resistant, this might have an impact on the PMI. 
 However, pain prevalence and pain intensity alone are not enough to illustrate the 
problem of cancer pain. Interference of pain with daily activities should also be taken into 
account. Although pain related interference with daily activities has been well studied16-19, 
pain management patterns are poorly understood in medical oncology outpatients. 
 A recent study by Fisch and authors reported pain prevalence, pain management 
adequacy and pain related interference with daily activities32. They found the same 
prevalence of moderate to severe pain as in the present study. However, they did not 
report on interference with daily activities of mild pain, neuropathic pain characteristics 
and breakthrough pain32. To get more insight in pain management patterns, our study 
explored the combination. Our findings are in line with those of Vallerand et al. They 
studied 304 oncology outpatients who experienced cancer-related pain within the past 
two weeks33. 
 Shi et al have previously reported that recall of worst pain in the last week contributes 
the most to patient reports of pain interference with daily activities34. 
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Conclusions
In conclusion, pain remains a significant problem in medical oncology outpatients. As 
adequate pain relief for up to 86% of patients with cancer should be feasible, pain in 
medical oncology outpatients is still undertreated.
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future research on the possibilities of using interference of pain with daily activities as an 
additional factor and not only as a determining factor for pain intensity categories. As 
patients often are reluctant to talk about their pain, it might be interesting to ask patients 
additionally about interference with daily activities related to their pain intensity. Pain 
might become more related to daily life and less to disease and medicine. Thus multi-
dimensional tools to assess cancer pain, taking into account interference with daily activities 
and predictors of pain, will facilitate improvements in cancer pain management.
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Introduction
Pain is one of the most prevalent symptoms of patients with cancer1, which hampers daily 
activities2 and quality of life3–5. Cancer pain is also associated with anxiety, depression, and 
sleep disturbances3–5. Prevalence of pain ranged from 27%6 to 60%7 in patients with 
cancer visiting outpatient clinics. Inadequate pain treatment ranged from 31%8 to 65%6 in 
patients with cancer. Although adequate pain relief in 71%9 to 86%10 of cancer pain is 
considered feasible, pain is still undertreated. Despite the availability of many evidence- 
based therapies for cancer pain and clinical practice guidelines (CPGs)11–13, pain in patients 
with cancer is still a major problem.
 Systematic pain assessment and documentation using a validated pain assessment 
tool, such as a visual analogue scale (VAS) or numeric rating scale (NRS), at each visit of the 
most recent CPGs on cancer pain management11,14. However, pain was not systematically 
assessed and documented15,16. Infrequently pain documentation leads to inadequate 
pain management. Systematic screening and documentation of pain are essential for 
quality improvement of cancer pain treatment, because a key patient-related barrier is 
that patients are reluctant to discuss pain with the doctor or to ask for pain medication17,18. 
This hesitation has a variety of reasons, including concerns about addiction and fear that 
reporting pain will distract the physician from the treatment of their cancer17. Additionally, 
care providers tend to show lack of attention to and knowledge about pain management18.
 Ineffective pain communication between physicians and patients19 and inadequate pain 
assessment contribute to inadequate pain management20,21. Thus, healthcare professionals 
should systematically ask for pain and document it22,23.
 The patient’s medical record should be the primary source of information about pain 
or its absence, as it gives the opportunity to monitor pain, treatment, and side effects over 
time24–26. 
 Accurate and consistent cancer pain registration improves the perception of physicians 
concerning cancer pain and enhances pain management18,24. No recent data on cancer 
pain registration have been published. Earlier studies do not report on pain registration by 
oncologists or in a small sample of oncologists from a single outpatient practice15,16. Little 
is known about the frequency and how pain is registered in medical records of medical 
oncology outpatients. This study on the documentation of pain in Dutch outpatient 
oncology clinics explored an important area for quality improvement in cancer pain 
management, whereas systematic pain assessment and documentation are essential in 
cancer pain treatment. Therefore, we explored registration of pain by the medical 
oncologist in medical records of outpatients with cancer.
Abstract
Background. Systematic pain registration and assessment with a visual analogue scale 
(VAS) or numeric rating scale (NRS) at each visit are key recommendations in one of the 
most recent guidelines on cancer pain management. It is unclear whether this 
recommendation is applied. The aim was to explore registration of pain in medical records 
of patients visiting the medical oncology outpatient clinic. Methods. In a multi-centre 
study in six Dutch hospitals, data were extracted from medical records of 380 outpatients 
with cancer. Data of the first three visits at the outpatient clinic were studied. Descriptive 
statistics were conducted. Results. In 23% of all 987 visits at the outpatient clinic, pain 
or absence of pain was registered, and in an additional 15% a nonspecific symptom 
description was given. Regarding all other visits, (62%) pain or absence of pain was not 
documented at all. Pain measurement using a VAS or NRS was documented in only one 
visit. Pain was more often registered in medical records of patients with metastasis, as well 
as in those of patients with urogenital tumours. Conclusion. Pain in medical oncology 
outpatients is not systematically registered in their medical records. With one exception, 
pain was not registered with a VAS or NRS. Yet, registration and assessment of pain in 
order to monitor pain are essential to evaluate and adapt pain treatment over time. Pain 
registration has not improved since 2001 and therefore, implementing the recommendations 
regarding systematic monitoring of pain is needed. 
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The following data were obtained from each medical record: patient characteristics 
(gender and age); disease characteristics (tumour type, intention of treatment (palliative/
curative); TNM stage (presence of metastasis and treatment); pain registration (all data on 
pain registration categorized as quantitative, qualitative, and nonspecific symptom 
description); and additional data (dates of the first three consultations and primary treating 
oncologist).
Categorized pain registration
Pain registration was categorized as quantitative, qualitative, or a nonspecific symptom 
description (adapted from Rhodes et al.)16. (1) Only documentation of a pain score was 
considered as quantitative pain registration; (2) Qualitative pain registration was defined 
as any other type of documentation of pain or absence of pain. It was categorized as: 
(A) Only documentation of pain or its absence, (B) A in combination with pain location, 
(C) A in combination with pain intensity or pain intensity change in words (e.g. pain is 
reduced), (D) As well A, B, and C; (3) Nonspecific symptom description was defined as 
any documentation of symptoms or their absence without specifically mentioning pain 
(e.g. no complaints, is doing well).
Methods
Study design and ethical consideration
In a multicentre study in six Dutch hospitals, retrospective data were extracted from 
medical records of outpatients with cancer. This study was conducted as part of a study 
that was granted by the Dutch Cancer Society (KWF)27 and has been approved by the 
Medical Ethics Committee (CMO) of the Radboud university medical center (METC 
protocol number 2011/020). The local ethical committees of each participating hospital 
have also approved this study. The ethical committees agreed that it was not advisable to 
ask patients to sign informed consent, because part of the population died and it might 
be too confrontational for others. 
Study setting 
Hospitals that were studied have both electronic and paper medical records, as they 
converted to electronic medical records in 2010 and 2011. These hospitals have protocols 
for nurses to record pain scores; however, nurses do report these scores in different 
medical records than oncologists. The hospitals are similar sized and have similar expertise 
as other Dutch medical centres.
Patients and data collection
In 2010 and 2011, data were extracted from paper and/or digital medical records of 
patients with cancer visiting an outpatient clinic of one of five general hospitals and one 
academic medical centre in the Netherlands. Available data were extracted both manually 
and electronically. Data were extracted by a medical student with practice experience. 
Medical records of patients were included, when patients were diagnosed with cancer 
and were 18 years or older. Medical records of patients were excluded if patients were not 
visiting the clinic for the first time (previously seen). For each excluded medical record, the 
medical record of the patient next in line of that month was analysed. Medical records of 
all medical oncologists (N = 28) of all participating hospitals were included in the study. 
Sampling methodology was used. First, to obtain an equal (and feasible) number of 
medical records per oncologist per setting, months were randomly assigned to medical 
oncologists (Figure 1). Second, a predetermined sample of patients was selected: the first 
three patients of each month visiting the outpatient clinic for the first time. Finally, a 
predetermined sample of visits was selected: the first three visits of the selected patients. 
For example, medical records of the first three patients each month visiting the outpatient 
clinic were obtained for months 1, 3, 6, and 9 of oncologist 1, months 2, 5, 8, and 11 medical 
records of oncologist 2, and months 4, 7, 10, and 12 of oncologist 3 (see Figure 1). The first three 
visits of these patients were analysed. When only one or two patients visited the outpatient 
clinic for the first time in a certain month, no additional medical records were extracted. 
Figure 1   Flow diagram data-collection
O= Oncologist; M= Month
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Statistics
Descriptive statistics were conducted with SPSS version 20 (IBM SPSS Statistics, Armonk, 
NY, U.S.A). Outcome variables were frequency of pain documentation (yes/no) and how 
pain was documented at first, second, and third consultation (quantitative pain registration, 
qualitative pain registration, and nonspecific symptom description). Additionally, patients’ 
 characteristics were identified for patients with and without pain documentation. Differences 
in proportions were tested with chi-squared test or Fisher’s exact test. Reported P-values 
are two-tailed and considered significant at the P≤ 0.05 level.
Results
A total of 395 medical records were selected for review. Although all of them were labelled 
as new patients with cancer in a digital overview database of medical records, 15 of them 
did not meet the inclusion criteria. Two medical records were of patients not diagnosed 
with cancer, 10 had visited the outpatient clinic before, and three medical records were 
not available. In total, documentation of 996 visits of 380 patients was obtained (Table 1). 
In nine visits of three patients, nothing was registered. These visits were reported as 
missing and were excluded from analysis. In total, 987 visits of 377 patients were analysed. 
Mean age of the patients was 61.3 ±13.9 (21 to 90). For patient characteristics, see table 2.
Table 2   Demographic characteristics of patients with and without pain registration* 
Characteristics Overall
(N=377)*
Pain registration 
(N=163)
No pain registration 
(N=214)
N N (%) N  (%)
Gender
Men 181 79 (43.6) 102 (56.4)
Women 196 84 (42.9) 112 (57.1)
Age groups in years
< 45 40 18 (45.0) 22 (55.0)
45-60 119 54 (45.4) 65 (54.6)
60-75 160 69 (43.1) 91 (56.9)
≥ 75 58 22 (37.9) 36 (62.1)
Primary cancer typea
Gastrointestinal 136 59 (42.8) 77 (56.6)
Urogenital 38 20 (52.6) 18 (47.4)
Breast 106 39 (36.8) 67 (63.2)
Lymphatic-haematological 28 8 (28.6) 20 (71.4)
Other ( e.g. lung, skin, glands, bone) 67 37 (55.2) 30 (44.8)
Unknown 2 0 (0.0) 2 (100.0)
Metastasisa
No 129 50 (38.8) 79 (61.2)
Yes 107 60 (56.1) 47 (43.9)
Unknown 141 53 (37.6) 88 (62.4)
Years between diagnosis and first consult
<1 286 122 (42.7) 164 (57.3)
1 - 2 23 11 (47.8) 12 (52.2)
2-5 27 14 (51.9) 13 (48.1)
>5 28 13 (46.4) 15 (53.6)
Unknown 13 3 (23.1) 10 (76.9)
Year of first consult 
2010 200 96 (48.0) 104 (52.0)
2011 177 67 (37.9) 110 (62.1)
a Chi-square test or Fishers exact test p≤0.05 (2-sided); *Pain registration in one or more out of three first con-
sultations. Data on pain registration of three patients of 380 were missing. 
Table 1   Data-collection characteristics 
Hospital No. of patients No. of physicians No. of visits *Missing
N (%) N (%) N (%) N (%)
A 63 (16.5) 5 (17.9) 168 (16.9) 1 (11.1)
B 44 (11.5) 5 (17.9) 121 (12.1) 6 (66.7)
C 63 (16.5) 3 (10.7) 149 (15.0) 0 (0.0)
D 72 (18.9) 2 (7.1) 193 (19.4) 0 (0.0)
E 72 (18.9) 2 (7.1) 202 (20.3) 0 (0.0)
F 66 (17.3) 11 (39.3) 163 (16.4) 2 (22.2)
Total 380 28 996 9
*Missing documentation of  3 patients = 9 visits; A-E = non-academic medical centre, 
F= academic medical centre
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Variation between consultations
Figure 3 shows frequencies of pain registration in sequential visits. Of all 380 patients, 329 
also had a second visit and 287 a third visit by the same oncologist. In 27.1% of all first 
consultations, the existence or absence of pain was registered. In 17.6%, a nonspecific 
symptom description was given, whereas during second (respectively, 21.0% and 12.2%) 
and third visits (respectively, 19.9% and 14.6%), this frequency decreased (P = 0.009).
Pain registration
In 229 of 987 visits (23.2%), pain or its absence was registered. Quantitative pain registration, 
with a VAS, was only recorded in one of 987 visits. In 228 of 987 visits (23.1%), qualitative 
pain registration was used. Of these, 39 (17.1%) were illegible, in 140 (61.4%) visits pain was 
reported, and in 49 (21.5%) visits the absence of pain was reported. In 17 (12.1%) of 140 
visits reporting pain, only pain or its absence was registered; in 78 visits (55.7%), pain, as 
well as pain location, was registered; in 13 visits (9.3%), pain and intensity, or pain intensity 
change was registered in words (e.g. less pain, pain is worse, decreased pain, moderate 
pain). Moreover, in 28 visits (20.0%) as well pain, pain intensity or intensity change in words 
and location of the pain were documented. Finally, data were illegible in four visits. In 
14.8% of all 987 visits, pain description was nonspecific. The majority of nonspecific 
symptom descriptions referred to absence or reduction of symptoms (e.g. is doing well, 
no complaints, is feeling well, is doing better).
Variation between hospitals
Figure 2 and table 3 show frequencies of pain registration per hospital. It shows that the 
academic medical centre most frequently registered pain (41.6%) and in another 19.3%, 
a nonspecific symptom description was given (academic vs. non-academic P = 0.000). 
As overall mean of all hospitals in 23.6% of the visits, pain or its absence was documented 
and additionally, a nonspecific symptom description was recorded in 14.8% of visits.
Figure 2   Analgesic pain treatment in relation to pain severity*
*chi-square test significant at p≤0.05 (2-sided); F=academic medical centre vs. A-E= non-academic medical 
centre (p=0.00)
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Table 3  Pain registration N(%)
Hospital Total  
visits*
Registration of  
pain or its absence
Registration of  
a non-specific  
symptom description
No pain  
registration
N N (%) N (%) N (%)
A 167 24 (14.4) 43 (25.7) 100 (59.9)
B 115 32 (27.8) 7 (6.1) 76 (66.1)
C 149 26 (17.4) 19 (12.8) 104 (69.8)
D 193 41 (21.2) 29 (15.0) 123 (63.7)
E 202 39 (19.3) 20 (9.9) 143 (70.8)
F** 161 67 (41.6) 31 (19.3) 63 (39.1)
Total 987* 229 (23.2) 149 (15.1) 609 (61.7)
* Number of visits without visits (n=9) of which documentation is missing; ** Chi-square test was significant at 
p<0.05 (2-sided); F= academic medical centre vs. A-E= non-academic medical centre (p=0.00)
Figure 3   Pain registration by consultation
*chi-square test significant at p>0.05 (2-sided); Difference between consultations p=0.01
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Van den Beuken et al. found that patients with more advanced stages of cancer were more 
at risk for pain28. Although systematic pain assessment and pain registration during each 
outpatient visit are recommended in the Dutch CPG on pain in patients with cancer24, our 
figures show a lack of implementation of this recommendation. Therefore, an RCT to evaluate 
an implementation strategy with training for medical staff and short message service (SMS), 
interactive voice response (IVR) for patients is running in six Dutch hospitals27. Our study has 
several strengths. First, we conducted a large, multicentre study. Second, we included 
medical records of all medical oncologists of all participating hospitals of a period of 2 years. 
 Medical records (paper or electronic version) of both patients with and without pain 
were studied, and finally, this is the first study that also included nonspecific pain descriptions 
as a separate category. 
 Our study assessed pain registration for both patients with and without pain. We 
documented the absence of pain to avoid nonspecific symptom descriptions and monitor 
pain over time. Additionally, our study included nonspecific pain descriptions as separate 
category. Nonspecific symptom questions do not specify whether a patient has pain, the 
intensity of pain, and whether it changes over time. Nonspecific symptom questions 
might not help patients to initiate talking about their pain with their physician.
 Our study also has some limitations. First, our data might not be representative for 
other European countries. Gynaecological-related cancers were hardly included in this 
study because these patients are not primarily treated by a medical oncologist in the 
Netherlands. Additionally, we were not able to distinguish between cancer-related pain 
and non-cancer related pain, as this information was not available in the medical records.
 Third, a sampling methodology was used; therefore, this study does not cover all pain 
documentation. However, we are convinced that data are representative for documentation 
of oncologists in these Dutch hospitals because all oncologists participated and months 
were randomized. The data are representative of the multi-institutional, but do not cover 
all documentation. Finally, oncologists might screen for pain but do not document it, 
and we do not know whether the general hospitals are representative for other hospitals. 
Our study shows several issues for further research. Implementation strategies for 
guidelines to improve systematic pain screening and registration and implementing the 
recommendations regarding systematic monitoring of pain is needed. 
 Despite the fact that pain prevalence is high in patients with cancer, its treatment is 
inadequate, it severely impacts quality of life7, and patients are reluctant to talk about 
pain17,18, we found that screening for pain with a VAS or NRS appeared practically absent. 
Previous studies have shown that accurate and consistent cancer pain registration improves the 
perception of physicians concerning cancer pain and enhances pain management17,23,18,24. 
Implementing the recommendations regarding systematic monitoring of pain is needed: 
(1) Pain should be systematically screened and registered in oncology outpatients at each 
visit; (2) Use pain-specific questions, because patients are reluctant to report pain; (3) 
Document absence of pain.
Pain registration by patient characteristics
Gender, age, years between diagnosis and first consultation, and year of first visits were 
not related to pain registration (Table 2). Pain registration (in one or more of the three 
visits) was more common in patients with urogenital tumours (52.6%) and less common in 
patients with breast cancer (36.4%) (overall P = 0.027). Additionally, pain registration was 
more common in patients with metastasis (55.6%) than in those without metastasis 
(38.5%) (P = 0.003).
Discussion
This study reveals that in the majority of medical records of oncology outpatients, pain 
was not systematically registered. We found that in only one of four visits, pain or its 
absence was registered. Pain scores with a validated scale were absent, with an exception. 
Since 2001, pain registration has not improved despite that systematic pain documentation 
has shown to be feasible in a busy outpatient oncology practice and is sustainable over 
time16. Previous studies have either not reported on pain registration by medical oncologists 
or reported only small samples from single outpatient clinics15,16.
 In 1999, Weber et al. also analysed medical records of outpatients with cancer and 
severe pain and found that only three of 12 physicians registered pain severity in more 
than 15% of their consultations15. We not only analysed medical records of patients known 
with pain, but of all outpatients with cancer. Their results are shown as number of 
physicians reporting pain severity, whereas we reported the percentage of visits in which 
pain was reported, which makes comparison with our results difficult.
 Another study by Rhodes et al. found that health providers and health assistants at 
the radiation and medical oncology outpatient clinic did not routinely assess pain16. 
Additionally, Rhodes et al. showed that, before training, physicians never documented 
quantitative pain assessment in their medical records. In their study, qualitative pain 
registration by physicians was higher in medical (53.8%) and radiation oncology (72.7%) 
than in ours (23.2%)16. Unlike Rhodes et al., we made a distinction between quantitative, 
qualitative, and nonspecific symptom registration in oncology outpatient clinics16. As well 
as the study of Weber as that of Rhodes shows that in the majority of medical records, pain 
was not systematically registered 12 years ago15,16. In our study, we found that pain was 
more often registered in first visits than in second and third visits.
 Often, during second and third visits, anticancer treatment has already started, which 
often causes pain. Therefore, in second and third visits, systematic screening for pain is 
even more important than in the first visit.
 Additionally, pain was more often registered in patients with urogenital tumours and 
in patients with metastasis. This is important because pain management in specific 
patient groups needs more attention28. 
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Conclusion
Pain in medical oncology outpatients is not systematically registered in their medical 
records. With one exception, pain was not registered with a VAS or NRS. Yet, registration 
and assessment of pain in order to monitor pain are essential to evaluate and adapt pain 
treatment over time. Pain registration has not improved since 2001 and therefore, 
implementing the recommendations regarding systematic monitoring of pain is needed. 
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Introduction
Pain prevalence in patients after curative treatment is 33%, 59% during curative treatment, 
and 64% in patients with metastases or an advanced disease stage1. Pain is undertreated 
in 31%2 to 65%3 of these patients, although adequate pain relief is considered feasible in 
86% of patients with cancer4. These figures show that pain is a major problem in all cancer 
stages. Pain is one of the most frequently feared symptoms for patients5,6 and is associated 
with anxiety, depressed mood, and sleep disturbances6-9. For those reasons, pain in 
patients with cancer strongly hampers patients’ daily activities10 and decreases their 
quality of life7-9.
 It has been shown that treatment of pain in combination with treatment of anxiety, 
depression, and sleep disturbances related to pain was more effective than pain 
medication alone11. However, physicians tend to show lack of attention for and knowledge 
about pain management12, do not systematically assess pain13,14, and inadequately 
communicate with patients about their pain15. Besides, for a variety of reasons, patients 
are reluctant to discuss pain with their doctor12,14,16. Some patients, for example, have 
concerns about addiction to pain medication, and others fear that reporting pain will 
distract the physician from cancer treatment16.
 Therefore, systematic screening and documentation of pain are essential. Clinical 
Practice Guidelines (CPGs) can be helpful to improve cancer pain management11,17,18. 
Systematic screening and documentation of pain are recommendations in the Dutch 
multidisciplinary evidence-based CPG “pain in patients with cancer,” one of the most 
recent CPGs on this subject in Europe and developed in 200811. This Dutch CPG has high 
quality regarding the process of development and the way of reporting19. It has been 
developed for all professional caregivers involved in cancer pain treatment, including 
medical oncologists. 
 As medical oncologists play a key role in planning, delivering, and coordinating cancer 
care and pain management in these patients, it is important to assess whether they are 
familiar with this CPG and adhere to its recommendations. 
 For this reason, a case vignette including most important recommendations of the 
CPG has been developed. A case vignette is an accurate tool for measuring care practices20. 
The objective of the case vignette study was to assess whether medical oncologists in the 
Netherlands adhere to the evidence-based recommendations in the Dutch cancer pain 
CPG as well as their confidence with treatment choices.
Methods
A national cross-sectional case vignette survey describes a patient with intractable pancreatic 
cancer and pain (see appendix I). 
Abstract
Background. Pain is a major problem in all cancer stages. Cancer pain guidelines are 
developed to improve management of pain. It is unclear whether these recommendations 
are applied in daily practice. Therefore, the objective of this study was to assess medical 
oncologists’ adherence to an evidence-based clinical practice guideline in cancer pain 
management and their confidence in treatment choices. Methods. A cross-sectional 
case vignette survey describing a patient with intractable pancreatic cancer and pain was 
sent to all 268 medical oncologists registered at the Netherlands Association of Internal 
Medicine. Descriptive statistics were conducted. Results. Sixty-three of 268 medical 
oncologists (24%) completed the survey. Adherence to the different recommendations of 
the guideline ranged from 18 to 100%. Confidence for treatment choice ranged from 
5.6 to 9.5 on a Numeric Rating Scale (0–10). Most of the responding oncologists (94%) 
adhered to prescribing paracetamol as first-line pain treatment, and all prescribed a 
laxative in combination with opioids to prevent constipation. However, only 24% of the 
respondents adhered to the guideline when first-line treatment had insufficient effect. 
Additionally, only 35% adhered to the recommendation for insomnia treatment providing 
psychosocial support or using a multidimensional pain questionnaire besides pharmaco-
logical treatment. Finally, only 18% adhered to the recommendation to perform a multi-
dimensional pain assessment when disease worsens and pain increases. Conclusions. 
The recommendations of the guideline have been partly adopted in cancer pain practice 
by medical oncologists. Particularly, pain assessment is not applied in the recommended 
manner. Therefore, implementation strategies should focus on adequate pain assessment 
in patients with cancer.
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Results
Initially, the response rate was 15%. After the first reminder, it increased to 21% and after 
the second reminder to 24% (63 medical oncologists) (Figure 1). Mean age of the medical 
oncologists was 45 ± 8.9 years (32–65 years). Oncologists estimated that 41± 21% (5–90%) 
of their patients with cancer have pain. Almost all respondents (94%) reported to be 
familiar with the CPG (Table 1). Eleven of 205 nonrespondents reported a reason for not 
responding; five medical oncologists did not want to participate, two reported that they 
receive too many questionnaires and were not able to answer all, one reported that there 
was not enough clinical information given to answer the questions and finally, three 
reported that they were too busy.
Study procedure
Of all 304 medical oncologists registered at the Netherlands Association of Internal 
Medicine (NIV), 36 were excluded because they were retired (n=7), were working in a 
foreign practice (n=11), were not a medical oncologist (n=4), were not clinically active 
(n=4), or could not be linked to a hospital or practice (n=10) (Fig. 1). This information was 
obtained from hospital Web sites, secretaries, or from the oncologists themselves after 
having sent the vignette for the first time.
 The remaining 268 medical oncologists were invited to participate in this study in 
October 2013. Nonrespondents received a reminder 3 weeks later and a second e-mail 
remainder 3 weeks after the first reminder. All questionnaires received before 1 February 
2014 were included in the analysis.
Case vignette
According to Hughes and Huby “vignettes consist of text, images or other forms of stimuli 
to which research participants are asked to respond”21. The case vignette used, concerned 
a woman with pancreatic cancer and was developed by two anesthesiologists who, 
respectively, participated in and chaired the Dutch cancer pain CPG development group 
in 2008 (KB, KV). It was pilot tested in four physicians. 
 The case vignette was divided in four consecutive parts, in which the disease stage 
worsens and the pain increases. Part I concerns questions on first-line pain management; 
part II describes an adaptation of pain treatment; part III concerns how oncologists 
manage pain-related impairment; and Part IV relates to end-of-life pain management. The 
case vignette consisted of 14 questions reflecting the most important recommendations 
of the CPG. Additionally, demographic characteristics of the respondents were assessed 
(gender, date of birth, number of years of experience in clinical practice, working in an 
academic/ non-academic hospital), the number of patients with cancer on their yearly 
patient list, an estimation of the percentage of these patients in pain, and whether the 
respondents were familiar with the Dutch CPG pain in patients with cancer. Finally, we 
asked them to report per question how confident they were with their treatment choice. 
Confidence in treatment choice was assessed on a Numeric Rating Scale (NRS) with 0 
being “not confident at all” and 10 being “completely confident.” Additionally, most 
common answers or combination of answers were shown.
Statistical analysis
Descriptive statistics were conducted. Percentages of medical oncologists adhering to 
the recommendations of the CPG were assessed. Statistical analyses were performed with 
SPSS 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
Figure 1   Study flow diagram
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pain assessment with a multidimensional pain questionnaire, and/or referral to a psychologist 
(Table 2, Q8). The recommendation to prescribe a benzodiazepine was followed by 73% 
of the respondents (Table 2, Q9). Despite this treatment, the patient still has sleeping 
problems and experiences severe anxiety for future suffering. Seventy-five percent of the 
respondents would discuss patient’s problems in a multidisciplinary team meeting and/or 
refer the patient to a psychologist, as recommended by the CPG (Table 2, Q10). 
Part I first-line pain management
Table 2 shows oncologists’ adherence to the recommendations of the CPG. Sixty-five 
percent of the respondents adhered to the recommended first-line pain management 
strategy. This includes at least pharmacological treatment and assessment of pain with 
a one-dimensional or a multidimensional pain questionnaire. Ninety-four percent of 
the respondents reported to prescribe paracetamol (and an NSAID) and not codeine as 
first - line pharmacological treatment. Figure 2 shows the most frequently reported answers 
or combination of answers. Most often, respondents (32%) reported as first-line pain 
management strategy pharmacological treatment, pain assessment with a one-dimensional 
pain scale, and further diagnostics (Fig. 2a, Q1). Thirty-eight percent of the respondents 
reported to prescribe paracetamol as single first-line pharmacological treatment. In addition, 
27% of the respondents reported to prescribe paracetamol in combination with a strong 
opioid, which is recommended in the CPG as second step in pain management and not 
as first step. Finally,10% of respondents reported to prescribe paracetamol and NSAIDs 
(Fig. 2a, Q2).
Part II adaptation of pain treatment
In part II of the case vignette, patient’s pain increases, and first-line pain treatment has 
insufficient effect. Adaptation of pain treatment is needed. Twenty-four percent of the 
respondents adhered to the recommendations of the CPG by at least adapting pharma-
cological treatment, conducting pain assessment with a one dimensional pain scale, and 
discussing possibilities for invasive treatment with an anesthesiologist (Table 2, Q3). Besides, 
much variation in answer or combination of answers existed for question 3 (choosing a 
strategy for adaptation of pain treatment)(Fig. 2B).
Eighty-nine percent of the respondents, as recommended, would add a strong opioid to 
paracetamol (and NSAIDs), which was already prescribed in the previous treatment phase 
(Table 2, Q4), and all respondents prescribed a laxative to prevent constipation caused by 
opioids (Table 2, Q5). The invasive treatment as part of the adapted pain management 
strategy should be a celiac plexus block and/or a splanchnic nerve block for patients with 
pain located in the upper abdomen, caused by primary tumour or metastases, which was 
chosen by 78 % of the respondents (Table 2, Q6). 
Part III impairment of pain
In part III of the vignette, the patient has concerns about her children: How will they cope 
with the fact that she will die. The CPG recommends to consider psychosocial support, as 
this can also improve pain control. However, to whom the patient should be referred to 
for help is not specified in the CPG (Table 2, Q7). The patient’s pain intensity is decreased, 
but insomnia is still a problem. Thirty-five percent of the respondents adhered to the 
recommendations for insomnia treatment by adaptation of pharmacological treatment, 
Table 1   Participants and practice characteristics of survey respondents (N=63)
N (%)
Gender
Man 26 (41.3)
Women 37 (58.7)
Age (years)
30-45 33 (52.4)
45-60 23 (36.5)
≥60 7 (11.1)
Years’ experience in practice
<1 3 (4.8)
1-5 22 (34.9)
5-10 12 (19.0)
>10 26 (41.3)
Practice type 
Academic 19 (30.2)
Non-academic 43 (68.3)
Other 1 (1.6)
Estimated number of  patients per year consulted 
50-100 4 (6.3)
100-500 32 (50.8)
=>500 21 (33.3)
missing 6 (9.5)
Percentage of patients with  cancer and pain
<10% 2 (3.2)
10-25% 15 (23.8)
25-40% 12 (19.0)
40-55% 17 (27.0)
55-70% 7 (11.1)
>70% 8 (12.7)
Missing 2 (3.2)
Are you familiar with the CPG? 
Yes 59 (93.7)
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Table 2   Adherence to CPG and summaries of CPG recommendations
Questions Recommendation Answer % adh.*
Part I first line pain management
Q1  Strategy of  pain management Use a one-dimensional scale or multi-dimensional pain 
 questionnaire for pain assessment1-4. (p 26-27)
- Pharmacological treatment and pain assessment with a one-dimensional scale OR
- Pharmacological treatment and  multi-dimensional questionnaire.
65%
Q2  Treatment of pain Prescription of paracetamol as first step in pain treatment5, 6. 
(p 69)
- Paracetamol OR
- Paracetamol and NSAID
94%
Part II adaptation of pain treatment
Q3  Strategy of pain management Use a one-dimensional pain scale or multi-dimensional pain 
questionnaire for pain assessment1-4. (p 26-27) 
- Adaptation of pharmacological treatment and assessment of pain with a one-dimensional 
pain scale and discuss possible invasive treatment with anaesthesiologist.  
24%
Q4  Treatment of pain Use NSAIDS  in combination with paracetamol or opioids if 
these have insufficient effect.(p 73) 
- Depends on answer Q2. Paracetamol (and NSAID) are given as first-line treatment, here a 
strong opioid should be added. 
89%
Q5  Prevention of side effect Prescription of a laxative to prevent constipation and an anti- 
emetic drug if persistent nausea is present7-9. (p 104-105)
- At least prescribe a laxative. 100%
Q6  Choice of invasive treatment Celiac plexus block is recommended for patients with pain 
localized in upper abdomen as a result of metastasis.10 (p 147) 
- Celiac plexus block OR
- Splanchnic nerve block** OR
- Celiac plexus block and Splanchnic nerve block** 
78%
Part III Impairment of pain
Q7 Mourning management Psychosocial support can improve pain treatment and should 
be considered (p 139-140). Pain treatment needs to be multi-
dimensional. (p 125)
- Not specified in CPG. n/a
Q8 Strategy of insomnia treatment Use a multi-dimensional pain questionnaire for pain assessment 
1-4.  (p 26-27)  Psychosocial support can improve pain treatment 
and should be considered. (p139-140)
- Adaptation of pharmacological treatment and pain assessment with a multi-dimensional 
pain questionnaire OR
- Adaptation of pharmacological treatment and refer to psychologist OR
- Adaptation of pharmacological treatment and pain assessment with a multi-dimensional 
pain questionnaire and refer to psychologist
35%
Q9  Treatment of insomnia Prescribe a drug against insomnia: benzodiazepine or tricycle 
antidepressant. (p125) Pain treatment needs to be multi-
dimensional. (p 125) Treating insomnia can also reduce pain  
or pain experience. (p 124)
- Benzodiazepine 73%
Q10 Strategy of depression management Psychosocial support can improve pain treatment and should 
be considered. (p 139-140) Pain treatment needs to be multi-
dimensional. (p 125) 
- Discussing patient in multidisciplinary team meeting
- Refer to psychologist
- Discussing patient in multidisciplinary team meeting and refer to psychologist
75%
Part IV pain management in end of life
Q11  Strategy of pain management Thorough history and physical examination; further investigation 
on indication. (p 27) Use a one-dimensional pain scale or 
multi-dimensional pain questionnaire for pain assessment1-4. 
(p 26-27) Consider invasive treatment if adaptation of pharma-
cological treatment will not be effective to further reduce pain. 
(p 145-147)
- Adaptation of pharmacological treatment and multi-dimensional pain questionnaire OR
- Adaptation of pharmacological treatment and multi-dimensional pain questionnaire and 
discuss possible invasive treatment with anesthesiologist
18%
Q12 Treatment of pain management If pain reduction is not sufficient by using opioids, opioid- 
rotation is recommended, titration is necessary11-15. (p 90) 
- Opioid-rotation 65%
Q13  Choice of invasive treatment If oral and transdermal opioids have insufficient effect or to 
reduce their side effects, spinal opioid administration should be 
considered. (p 144)
- Spinal opioid administration 43%
Q14 Choice of administration route Change opioid administration route (oral, transdermal, 
 subcutaneous or intravenous). (p 95-96) 
- Subcutaneous 71%
*adherence to CPG =  percentage of respondents who treated the patient in adherence with the recommendations 
of the CPG, including respondents who also included other answer categories in their answer besides what 
has been recommended.  **shows much similarity with the celiac plexus block. 1-15 See appendix II additional 
references table 2
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Part IV impairment of pain
The patient’s pain intensity increases and the disease progresses. Eighteen percent of the 
respondents adhered to the recommendation of the CPG to adapt pharmacological 
treatment and to conduct pain assessment with a multidimensional pain questionnaire 
(Table 2, Q11). Sixty-five percent of the respondents suggest opioid rotation if pain 
reduction is not sufficient (Table 2, Q12). Besides, 43% of the respondents chose for spinal 
opioid administration as invasive pain treatment. If oral and transdermal opioids have 
insufficient effect or too many side effects, spinal opioid administration should be 
considered (Table 2, Q13). At home, the subcutaneous route of an opioid is recommended, 
to which 71% of the respondents adhered (Table 2, Q14).
Figure 2C Q7 shows that most frequently, the respondents would refer the patient to a 
psychologist, social worker, or pastoral worker (14%). Figure 2C Q8 shows that the most 
commonly chosen strategy for insomnia treatment (29%) was to adapt the pharmacological 
treatment without conducting pain assessment or referring the patient to a psychologist. 
Additionally, Fig 2C Q10  shows that most respondents would treat this patient for anxiety/
depression with treatments categorized as “other” (16%). For example, the respondents 
described strategies as talking with the patient about his/her concerns or discussing the 
medical status of the patient with the general practitioner or with the palliative care team.
Figure 2   Most common answers or combinations of answers (see notes figure 2 next page)
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Notes figure 2: 
First-line pain treatment: Q1  Strategy of first-line pain management: A=  pharmacological 
treatment, one-dimensional pain measurement and further diagnostics; B=  pharmacological 
treatment & one-dimensional pain measurement; C=  pharmacological treatment. Q2 Treatment 
of pain: A = paracetamol; B= paracetamol & strong opioid;  C= paracetamol & NSAIDS. Adaptation 
of pain treatment: Q3 Diagnose/characteristics of pain:  A= pharmacological treatment & asking 
about constipation & one-dimensional pain measurement; B= pharmacological treatment & 
asking about constipation & further diagnostics & one-dimensional pain measurement & contact 
anesthesiologist for invasive treatment; C= pharmacological treatment & asking about 
constipation.. Q4  Treatment of pain: A= strong opioid B= NSAID & strong opioid; C= NSAID. Q5 
Prevention of side effects: A=  a laxative; B= a laxative and anti-emetic. Q6 Choice of invasive 
treatment: A= celiac plexus block; B= celiac plexus block & spinal administration of opioid; 
C= celiac plexus block &  splanchnic nerve block. Impairment of pain : Q7  Mourning 
management: A= psychologist & social worker & pastoral worker; B= psychologist; C= psychologist 
& pastoral worker; D= other.  Q8 Strategy of insomnia treatment: A= adaptation pharmacological 
treatment; B= adaptation pharmacological treatment & consultation psychologist; C= other. 
Q9  Treatment of insomnia: A=benzodiazepine; B= benzodiazepine & other; C= other; 
D=benzodiazepine & anti-depressant. Q10 Strategy of depression management: A= Other; 
B= referral to clinical psychologist; C= multidisciplinary team meeting. Pain management in 
end of life: Q11  Strategy of pain management: A= adaption of the pharmacological treatment & 
discuss with anesthesiologist for invasive pain treatment; B= discuss with anesthesiologist for 
invasive pain treatment; C= adaption of the pharmacological treatment & one-dimensional pain 
measurement & discuss with anesthesiologist for invasive pain treatment; D= Adaption of the 
pharmacological treatment & one-dimensional pain measurement. Q12 Treatment of pain 
management: A=opioid rotation; B=further increase of opioid dose; C=parenteral administration 
of opioids. Q13  Choice of invasive treatment: A= celiac plexus block; B= spinal opioid 
administration; C= celiac plexus block & spinal opioid administration.  Q14 Choice of administration 
route: A= subcutaneous; B= transdermal; C= subcutaneous & transdermal.
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Besides, they also addressed the reluctance of patients to talk about opioids or to report 
pain as another key barrier in cancer pain management14. 
 Adherence to the recommendations regarding pain assessment appeared low as 
compared to the recommendations on pain treatment. A possible explanation might be 
that in the Dutch CPG, the recommendations for pain assessment are not specified: when, 
why, and how pain should be assessed. A substantial part of the recommendations of 
evidence-based CPGs is based on consensus opinion. If systematic reviews or large 
prospective studies are not available, evidence-based guidelines use expert opinion. In 
the Dutch CPG, the recommendation whether or not paracetamol should be continued 
when an opioid is prescribed is one of these recommendations  (see Table 2, Appendix 2). 
That might explain why opioids were prescribed early on for this scenario by 27% of the 
respondents. This recommendation on pain assessment should contain information on 
how and how often pain needs to be assessed. It should also mention when to make use 
of a one-dimensional pain scale and when to add a multidimensional pain questionnaire. 
Besides, structured registration of the results of the pain assessment in the medical record 
needs to be mentioned in CPGs as an essential part of the recommendation26. Second, 
publishing a CPG is not enough27. Implementation efforts are needed to improve cancer 
pain management, and examples should be given. Moreover, the CPG revision should 
focus on cancer pain management barriers, especially on ineffective patient -specialist 
communication. Additionally, the CPG recommends that psychosocial support should be 
considered as an essential part of the pain management strategy, because it can improve 
pain control. 
 However, to whom the patient should be referred to for this support is not specified 
in the CPG. Finally, a previously conducted study to assess how pain has been registered 
in medical records of patients with cancer by medical oncologists shows that pain was 
not systematically registered in their medical records and only in one out of 987 visits at 
the outpatient clinic pain was registered with an NRS or Visual Analogue Scale (VAS)26. 
Therefore, recommendations for pain registration in medical records should be included 
and specified in the CPG: how pain should be registered and who is responsible for 
registration. 
 The present study has several strengths. This is the first study to assess medical 
oncologists’ adherence to evidence-based cancer pain CPGs. Additionally, we asked all 
medical oncologists registered at the Netherlands Association of Internal Medicine (NIV) 
to participate. Another strength of this study is that the use of a case vignette is an accurate 
tool for measuring care practices and it gives more information than retrospective analysis 
of medical records to assess adherence to CPGs20.
 Several limitations of this study should also be considered in the interpretation of the 
findings. The overall response rate of 24% is low. However, other recently conducted 
surveys on cancer pain in medical oncologists also showed low response rates between 
15 and 33%14,24,25,28. 
 Figure 2D Q11 shows that most respondents (25%) would treat the pain with adaptation of 
pharmacological treatment and discuss possible invasive treatment with an anesthesiologist 
(Fig. 2D, Q11). 
Confidence in treatment choices
Respondents were asked to report per question how confident they were with their answer, 
which ranged from 5.6 to 9.5 on an NRS. The confidence figures did not differ between 
respondents who adhered to the CPG and those who did not, except for confidence with 
the strategy for depression treatment (question 10). Regarding this question, respondents 
who did not adhere to the recommendation of the CPG appeared more confident with 
the treatment choice than respondents who did not (p=0.043, two-tailed).
Discussion
The results of this national case vignette survey to assess medical oncologists’ adherence 
to evidence-based CPGs show that adherence to the recommendations of the CPG 
ranged from 18 to100%. Feeling confident with the chosen treatment ranged from 5.6 to 
9.5 on an NRS. Particularly, pain assessment was not applied in the recommended manner. 
As medical oncologists play a key role in planning, delivering, and coordinating cancer 
care and pain management, it is important that they systematically assess pain. Therefore, 
we recommend to implement a quality indicator for assessing cancer pain, in order to 
facilitate diagnosis, evaluation, and documentation of cancer pain22.
 A quality indicator for standardized postoperative pain assessment is already 
implemented in Dutch practice23. In our study, adherence to the recommendations 
appeared somewhat higher than that in an equal case vignette study with pain specialists 
in France24. This study by Piano et al. showed that half of the respondents adhered to the 
recommendations of a French CPG for neuropathic pain in patients with cancer24. 
Although overall adherence in our study was higher than in the French study, adherence 
to 4 out of 13 recommendations was very low. Besides, much variation in answer or 
combination of answers existed in question 3 (choosing a strategy for adaptation of pain 
treatment).
 Probably, this question was not well formulated which might have influenced adherence. 
Especially, adherence to pain assessment appeared to be low. An Australian survey among 
oncologists to identify barriers and facilitators to cancer pain assessment and management 
showed that only 22% of the respondents reported to use pain CPGs25. In agreement with 
our findings, they addressed that particular attention should be paid to promoting the use 
of validated pain assessment scales25.
 Additionally, another survey on attitudes of oncologists regarding cancer pain 
management showed that poor assessment is a key barrier in cancer pain management. 
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This relatively low response rate raises concerns whether the results can be generalized to 
the Dutch medical oncologists’ population. The responding medical oncologists probably 
were more interested in cancer pain management than nonrespondents, which might 
have caused higher adherence rates.
 For this reason, the low response rate will not have influenced our conclusion that 
pain assessment needs further implementation. 
 This national case vignette survey to assess whether medical oncologists adhere to 
an evidence-based CPG shows that the recommendations of the CPG have not been well 
adopted, especially the recommendation for conducting pain assessment. Additionally, 
the CPG should advice whether an anesthesiologist is needed in a more advanced stage 
of the disease. We would encourage other case vignette studies to report most common 
answers, besides adherence, to be able to discuss the quality of the questions included.
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Appendix I: Case Vignette 
Ms. A is 45-years old. She is married and has two children (12 and 15 years old). After she 
developed a silent icterus, an intractable pancreatic cancer was diagnosed. The family has 
been informed about her poor prognosis. The bile flow  was restored  using a stent. The 
patient is in good condition and has a good appetite. Ms. A is treated with chemotherapy.
A few weeks after hospital discharge, Ms. A visits the outpatient clinic because she has 
pain in her upper abdomen with varying intensity. 
1.  You decide to treat the patient with the following strategy (more than one answer is possible):
 Pharmacological treatment
 Pain assessment with an one-dimensional pain scale (pain intensity)
 Pain assessment with a multidimensional pain questionnaire
 Further diagnostics, namely…
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10  Being completely confident
2. The pharmacological treatment includes (more than one answer is possible):
 Paracetamol
	 Codeine
	 NSAID
	 Strong opioid
	 Other, namely….
	 N/A
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10   Being completely confident
The pain is acceptable for a couple of weeks. Then the pain increases. Ms. A experiences 
pain in her upper abdomen, especially during the night and she wakes up early in the 
morning because of her pain.
3.  You decide to treat the patient with the following strategy (more than one answer is possible):
	 Adaptation of the pharmacological treatment
	 Ask about possible constipation problems
	 Pain assessment with an one-dimensional pain scale (pain intensity)
	 Pain assessment with a multidimensional pain questionnaire
	 Contact an anesthesiologist for possible invasive treatment
	 Further diagnostics, namely….
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10  Being completely confident
27. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med 
Care 2001; 39: 46–54. 
28. Roth M, Davies D, Friebert S et al. Attitudes and practices of paediatric oncologists regarding methadone use 
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7.  The pain decreases because of treatment, however insomnia remains a problem. You 
decide to treat the patient with the following strategy (more than one answer is possible):
	 Adaptation of pharmacological treatment
	 Pain assessment with an one-dimensional pain scale (pain intensity)
	 Pain assessment with a multidimensional pain questionnaire
	 Psychological consultation
	 Other, namely……
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10   Being completely confident
8. The adaptation of pharmacological treatment includes:
	 Add a benzodiazepine
	 Add an antidepressant drug
	 Add methylphenidate
	 Other, namely……
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all    0   1   2   3   4   5   6   7   8   9   10  Being completely confident
Ms. A still suffers from insomnia after your treatment and tells you about her concerns for 
future suffering.
9. You decide to treat the patient with the following strategy (more than one answer is possible):
	 Discuss this patient in a multidisciplinary team meeting
	 Refer the patient to a clinical psychologist
	 Advice to contact a pastoral worker
	 Refer the patient to a nurse specialized in oncology
	 Prescribe an antidepressant drug
	 Other, namely……
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all  0    1    2    3    4    5    6    7    8    9    10  Being completely confident
After a short period of time the pain worsens and is localized in the whole abdomen. 
Illness progresses and the chemotherapy should be cancelled.
10. You decide to treat the patient with the following strategy (more than one answer is possible):
	 Adaptation of the pharmacological treatment
	 Pain assessment with an one-dimensional pain scale (pain intensity)
	 Pain assessment with a multidimensional pain questionnaire
	 Contact anesthesiologist for possible invasive treatment
	 Other, namely…
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all  0  1   2   3   4   5   6   7   8   9   10   Being completely confident
The adaptation of the pharmacological treatment includes:
	 Add paracetamol
	 Add NSAID
	 Add or increase codeine
	 Add or increase a strong opioid
	 N/A
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10   Being completely confident
4.  To treat or avoid possible side effects of strong opioids you prescribe the following 
medication:
	 A laxative
	 An anti-emetic
	 Medication or treatment to treat drowsiness
Please report how confident you are that this strategy is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10   Being completely confident
5. A possible invasive pain treatment:
	 Cordotomy
	 Celiac plexus block
	 Splanchnic nerve block
	 Hypogastric nerve block
	 Lower end block
	 Spinal administration of an opioid
	 Other, namely
	 N/A
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10   Being completely confident
Ms. A worries about her children’s reaction concerning her future death.
6. You suggest to contact additional help can be provided by:
	 Foundation “de Einder”
	 Foundation “Achter de Regenboog”
	 A psychologist
	 A social worker
	 A pastoral worker
	 Other, namely……
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11.  Despite optimal titration of the strong opioid the pain increases; which adaptation of 
the pharmacological treatment can be proposed?
	 Further increase of the opioid dose
	 Opioid rotation
	 Parenteral administration of opioids
	 Adjuvant treatment, namely…
	 N/A          
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all  0   1   2   3   4   5   6   7   8   9   10  Being completely confident
12. The possible invasive treatment is?
	 Cordotomy
	 Celiac plexus block
	 Splanchnic nerve block
	 Hypogastric nerve block
	 Lower end block
	 Spinal administration of an opioid
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all   0   1   2   3   4   5   6   7   8   9   10  Being completely confident
The patients wants no invasive pain treatment anymore. The disease is complicated by a 
pelvic venous thrombosis, which is treated with acenocoumarol. After a few weeks her 
situation further deteriorates. She is very tired and unable to eat and drink The patient 
can’t swallow the opioids. Her life expectancy is estimated one to two weeks.
13. What is the most suitable way of giving strong opioids at home?
	 Intraspinal
	 Subcutaneous
	 Transdermal
	 Intravenous
Please report how confident you are that this treatment is correct (please circle what applies)
Being not confident at all   0  1   2   3   4   5   6   7   8   9   10   Being completely confident
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Background
Pain is a major healthcare problem for patients with cancer1 and is one of the most 
frequently feared symptoms2,3. In 2007, in a Dutch study 64% of patients with metastatic, 
advanced, or terminal disease4, 59% of those on anti-cancer treatment and 33% of patients 
after curative treatment experienced pain4. Often, pain control is inadequate2-9. In 2007, 
Deandrea et al. demonstrated that pain is undertreated in 50% of patients with cancer10. 
For most patients acceptable pain reduction has not yet been reached. Up to now, no 
hospital-wide intervention has yet improved the treatment of pain11. 
 A key barrier in cancer pain management is ineffective communication between 
patients and healthcare providers about their pain12,13. Patients often consider information 
they receive from providers to be unclear14,15. Generally, patients lack knowledge about 
pain and pain management16,17. Several studies show that informing and educating the 
patient about treatment of cancer pain reduces pain intensity18-21.
 Professionals do not ask their patients systematically about their pain22,23. Moreover, 
patients seem to be reluctant to talk about their pain or to ask for pain medication24-26 for 
a variety of reasons, such as concerns about addiction, tolerance, desire to please providers, 
and fear that reporting pain will take the physician’s time away from the treatment of their 
cancer27,28. 
 One further aspect of underreporting pain concerns assessment and documentation. 
There is evidence that careful and regular, systematic assessment of pain improves the 
perception of physicians and nurses concerning cancer pain and enhances the quality of 
pain management29,30.
 Healthcare providers lack attention to and knowledge about pain management29,31-33 
and consequently do not always treat pain according to specific guidelines31,32. This has 
been regarded as one of the main factors causing inadequate pain relief in patients with 
cancer29,34,35. 
 For these patient- and professional-related reasons, inadequate treatment of cancer 
pain persists, despite decades of efforts to provide clinicians with information on analgesics 
and pain-relieving techniques36-42, and despite the availability of evidence-based guidelines 
on cancer pain43. 
 The prevailing principle for treatment of cancer pain is the World Health Organization 
(WHO) three-step pain ladder, published in 198642. If this guideline is well applied, it is 
possible to achieve adequate pain relief in 70 to 90% of patients with cancer44-47. 
 Based on this pain ladder, a more detailed European recommendation for the use of 
morphine and alternative opioids has been published by the European Association for 
Palliative Care (EAPC)48. The final version of the ‘Evidence-based guidelines for the use of 
opioids analgesics in the treatment of cancer pain: The EAPC recommendations’ is in 
development49. 
Abstract
Background. One-half of patients with cancer have pain. In nearly one out of two patients 
with cancer and pain, pain was undertreated. Inadequate pain control still remains an 
important problem in this group of patients. Therefore, in 2008 a national, evidence-based 
multidisciplinary clinical practice guideline ‘pain in patients with cancer’ has been developed. 
Yet, publishing a guideline is not sufficient. Implementation is needed to improve pain 
management. An innovative implementation strategy, Short Message Service with Interactive 
Voice Response (SMS-IVR), has been developed and pilot tested. To evaluate on effectiveness 
of this strategy to improve pain reporting, pain measurement and adequate pain therapy. 
In addition, whether the active role of the patient and involvement of caregivers in pain 
management  may change. Method. A cluster randomised controlled trial with two arms 
will be performed in six oncology outpatient clinics of hospitals in the south-eastern 
region of the Netherlands, with three hospitals in the intervention and three in the control 
condition. Follow-up measurements will be conducted in all hospitals to study the 
long-term effect of the intervention. The intervention includes training of professionals 
(medical oncologists, nurses, and general practitioners) and SMS-IVR to report pain in 
patients with cancer to improve pain reporting by patients, pain management by medical 
oncologists, nurses, and general practitioners, and decrease pain intensity. Discussion. 
This innovative implementation strategy with technical tools and the involvement of 
patients, may enhance the use of the guideline ‘pain in patients with cancer’ for pain 
management. Short Message Service alerts may serve as a tool to support self-management 
of patients. Therefore, the SMS-IVR intervention may increase the feeling of having control. 
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Methods
Objectives/hypothesis
The primary objective of this RCT is to reduce pain intensity of patients with cancer. 
The secondary objectives are to improve knowledge of the guideline to increase pain 
reporting by patients and professionals, to increase systematic pain measurement by 
medical specialists and nurses working at oncology outpatient clinics, and increase quality 
of life of patients.
 It is hypothesized that this innovative implementation strategy—which includes use 
of technical tools, training of professionals, and patient involvement—may increase the 
use of the guideline for pain management in patients with cancer, and consequently 
reduce pain intensity (individual level and cluster level) and increase pain management. 
SMS-IVR alerts may serve as a tool to support self-management of patients. 
Time frame 
This study will be conducted from 2011 to 2015.
Study design 
A non-blinded cluster RCT, will be performed in six oncology outpatient clinics of hospitals 
in the south-eastern region of the Netherlands, with hospital as cluster. Stratified 
randomisation will be performed based on pairs of two comparable hospitals regarding 
number of beds and number of medical oncologists. For each pair, one hospital will be 
randomly allocated to the intervention condition and the other to the control condition. 
Allocation to the intervention or control condition will be done before start of the 
intervention period by asking a statistician to select three closed envelopes (Figure 1). The 
allocation was generated by an independent statistician. 
Chosen implementation strategies are:
1. Training of oncologists and nurses involved in cancer care on the most important 
aspect of the CPG comprising of three one-hour sessions, one main session at baseline, 
session two at month six, and the final session at month twelve (intervention arm).
2. Patients will receive SMS-IVR and personal advice by phone on how to reduce their 
pain if their pain rating is 5 or higher on a numeric rating scale (NRS) of 0 (no pain at 
all) to 10 (worst pain you can imagine) (intervention arm).
3. Patients will receive a leaflet on cancer pain of the Dutch Cancer Society (in both arms).
4. Oncologists and nurses will receive a leaflet for professionals on pain treatment of the 
Comprehensive Cancer Centre organisation (VIKC) (both arms). 
5. GPs in the Netherlands will be offered a web-based training on the most important 
aspects of the CPG (intervention arm). 
 The Dutch guideline ‘Pain in patients with cancer’50 is one of the most recent 
guidelines on this topic in Europe. It combines new insights and existing knowledge 
derived from evidence-based medicine. All relevant professional organizations of the 
Netherlands as well as the patient association have been involved in the development 
process. In a comparative study of European guidelines on this topic with the AGREE II 
instrument, this Dutch guideline appeared to have followed a good development process51. 
Yet, under-treatment of cancer pain may be partly caused by a lack of implementation of 
these clinical practice guidelines (CPGs)10,52-54. 
 The present study aims to evaluate the implementation of the Dutch guideline ‘Pain 
in patients with cancer’50 to improve pain reporting, pain measurement, and hence pain 
control in patients with cancer and pain. A randomised controlled trial (RCT) with two 
arms will be performed in which professionals will be trained and Short Message Service 
with Interactive Voice Response (SMS-IVR) will be used to monitor and report pain. 
 Using Short Message Service (SMS) as a reminder and as tool to collect data on pain 
scores is innovative and promising55. Mobile phones are part of daily life; in 2009, nine out 
of ten Dutch inhabitants used a mobile phone56. 
 SMS alerts have been used for asthma management57-59, management of irritable 
bowel syndrome60,61management of diabetic patients61 and recurrent pain in children 
aged 9 to 1562. These studies concluded that SMS can serve as a tool to support self-man-
agement of patients. The use of mobile phone SMS alerts in the present study may be a 
way to encourage patient empowerment, because the patients’ role in their pain 
management becomes more active. Empowerment has been defined by its absence of 
helplessness, or the feeling of having greater control over one`s life63. 
 We expect that SMS-IVR will increase the percentage of patients with cancer who 
receive adequate pain treatment and reduce pain intensity in patients with cancer, because 
pain will be measured systematically. In addition, patients are expected to become less 
reluctant to report pain and physicians will ask patient more frequently about pain.
 The primary research question of the present study is: Will implementation of the Dutch 
guideline improve pain reporting, pain measurement, and adequate pain therapy?
A RCT will be implemented, with clustering based on number of beds and number of 
medical oncologists to increase comparability of hospitals and to reduce contamination64. 
Differences of the effectiveness of the intervention between subgroups are expected. 
Factors that may predict inadequate cancer pain treatment include gender, race, low 
education, a better physical condition without metastatic disease, and age65. This paper 
describes the aims and methods of an RCT to evaluate on effectiveness of implementation 
of the Dutch guideline to improve pain reporting, pain measurement, and adequate pain 
therapy. The results of this study will be published in several scientific papers. 
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older; pain intensity of 3 or more on an NRS for the worst pain experienced in the last 
24 hours; and having and being familiar with the use of a mobile phone. Overall exclusion 
criteria are: dementia and other severe cognitive disorders; no informed consent; and 
non-Dutch speaking and writing. 
Intervention 
The intervention was based on a pilot study with 13 patients, performed from November 
2009 to January 2010, to test feasibility of SMS-IVR. The mean response rate was 62%. 
A significant reduction of highest pain intensity was found between pre- and post-test 
(p = 0.018). Pain fluctuated more in patients included in this pilot study than would be 
expected in patients who will be included in the present study, because only patients in 
palliative care were included in the pilot study. 
 Next, we developed a multifaceted intervention with hospital as cluster. Multifaceted 
interventions are proven to be more effective than single interventions66,67. 
 Oncologists and nurses in the hospitals allocated to the intervention condition will 
be trained in-person, and GPs of patients that take part in the study will be offered a 
web-based training on the most important aspects of the CPG. 
Follow-up measurements in all hospitals will be conducted to study the long-term effect 
of the intervention. Regarding the patients recruited in this study, the intention to treat 
principle will be used (Figure 2). 
 Furthermore, four times, during a period of one week, transversal measurements will 
be performed in outpatient clinics of all six hospitals. Pain intensity of all patients who visit 
the oncology outpatient clinic during that week will be measured. 
Participant recruitment and inclusion- and exclusion criteria
To recruit hospitals, a letter was sent to hospital boards. If the board was willing to 
cooperate, a meeting with the oncologists and nurse practitioners in oncology was 
arranged to introduce the study. All hospitals are recruited from the south-eastern region 
of the Netherlands. Via the hospital boards, professional caregivers, oncologists, and 
nurses involved in cancer care of the six participating hospitals will be invited to take part. 
Patients who visit the oncology outpatient clinic will be screened for possible inclusion. 
Patients will be invited to take part by their medical oncologist or research nurse if they 
start to experience cancer-related pain. 
Figure 1   Flowchart cluster randomisation of clinics
Figure 1 shows the cluster randomisation of clinics. A cluster RCT with two arms will be performed in six oncology 
outpatient clinics of hospitals, with three hospitals in the intervention and three in the control condition. Clusters 
of hospitals will be determined based on number of beds and number of medical oncologists. We require 35 
patients per hospital, a total of 210 patients.
6 hospitals 
Intervention
3 hospitals 
Intervention
3 hospitals 
Intervention
(N=105)
Control
(N=105)
Cluster randomisation
(3 x clusters of 2)  
Patients inclusion (total N =210)
Figure 2   Overall time chart of the study and per patient (M = month)
Figure 2 shows the overall time-chart of the study and per patient. Each hospital has a period of twelve months 
to include 35 patients in the study. The total intervention period of hospitals is fifteen months (per patient twelve 
weeks). The first follow-up period is six months after the intervention period (M15) and the second, twelve 
months after the intervention period (M27). Each patient will be included in the study for 15 months. 
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In addition, both patients in the intervention and the control condition will fill in a pain 
diary on Tuesdays for 12 weeks; twice each Tuesday, once between 8:00 and 12:00 a.m., 
and once between 12:00 a.m. and 17:00 p.m.. However, there should be a  minimum of five 
hours between the morning and afternoon measurement. The pain diary reports pain 
intensity with an NRS, the use of pain medication, and any side effects of the medication. 
Patients will also receive a leaflet on cancer pain of the Dutch Cancer Society. In addition, 
oncologists and nurses will receive a leaflet for professionals on pain treatment of the 
VIKC. 
Control
Patients in the control condition will also receive a leaflet on cancer pain. These patients 
will complete a pain diary on Tuesdays during the 12-week period in the same way as the 
patients in the intervention condition. In addition, professionals will be offered a leaflet on 
pain treatment as a summary of the pain management guideline. 
 Patients in the intervention condition will get SMS-IVR and will receive an advice by 
phone how to reduce their pain if their pain rating is 5 or higher on a NRS (0 =no pain at 
all to 10 =worst pain you can imagine). The research nurse of the hospital, specialised in 
pain treatment and trained for this project, will provide the personal advice. 
 The training for oncologists and nurses consists of three one-hour sessions, all given 
in-person; one main session at baseline, session two at six months, and the final session at 
12 months. The first session will include the aim of the study, the main aspects of pain 
treatment in patients with cancer, pain measurement, and an instruction of the SMS-IVR 
system in detail. The next two sessions aim to summarise the first session and discuss 
problems associated with the implementation of the guideline. 
 Figure 3 shows the workflow of the SMS-IVR intervention. Patients receive SMS-IVR 
minimal once a week (Tuesdays), twice a day, during 12 weeks (Figure 2). SMS alerts are 
used as a reminder for patients that they will receive an automatic telephone call in 15 
minutes. SMS alerts will be received at 09:45 a.m. and at 2:45 p.m. At 10 a.m. and at 3 p.m. 
the patients will be called and invited to rate their pain on a scale of 0 (no pain) to 10 (worst 
pain imaginable). In the morning patients were asked to rate their pain by choosing a 
number that best describes their WORST pain in the last 24 hours. In the afternoon 
patients were asked to rate their pain at this moment.
 If the highest pain score is 5 or higher, the research nurse will contact the patient and 
will ask: ‘at what time/period the patients experienced the worst pain and whether the 
pain limited daily activities?’ 
Any patient with a pain intensity of 5 or higher on an NRS on Tuesday will again receive 
two SMS alerts the next day (Wednesday); the procedure will be repeated. For those who 
still have a pain score of 5 or higher on Wednesday, the procedure will be repeated again 
at Thursday. 
 The whole procedure of the SMS-IVR system is described in figure 3. For the days without 
SMS, patients will follow the instructions of the research nurse. 
Figure 3 shows the workflow of the SMS-IVR intervention. Patients receive SMS-IVR 
minimal once a week (Tuesdays), twice a day, during 12 weeks. SMS alerts are used as a 
reminder that they will receive an automatic telephone call 15 minutes later with IVR. SMS 
alerts will be received at 09.45 a.m. and at 2.45 p.m. At 10.00 a.m. and at 3.00 p.m. the 
patients will be called and invited to rate their pain on a scale of 0 (no pain) to 10 (worst 
pain imaginable). If the highest pain score is 5 or more, the research nurse will contact the 
patient. If a patient has five or higher on an NRS on Tuesday he/she will again receive two 
SMS alerts the next day (Wednesday); the procedure will be repeated. For those who still 
have a pain score of five or higher on Wednesday, the procedure will be repeated again at 
Thursday. The whole procedure of the SMS-IVR system described in figure 1 will start 
again the next week at Tuesday. 
Figure 3   Workflow SMS alerts
*If  the next day pain is graded  as ≥ 5 the oncologists will be informed. 
 
 
 
 
 
9.45 am and 2.45 pm patient receives 
a SMS-alert on their mobile phone  
At least one pain 
score ≤5 (NRS) 
10 am and 3 pm patient will be called 
by an automatic telephone call with  
Interactive Voice Response (IVR)   
No actions  
Research nurse wil l call patient within
2 hours and will ask specific characteristics 
of the pain and give an personalized 
advice how to reduce the pain.  
 
 NEXT DAY*  
EVERY TUESDAY  
Patient is asked to grade their pain 
intensity experienced in this morning
or afternoon. 
 
Patient does not answer call. Patient will
receive an extra SMS-alert after  
15 minutes and will be called again after 
30 minutes.  
 
Patient still does not answer 
call this will be reported as  
“Missing value” 
All pain scores  
 < 5 (NRS) 
 THIRD DAY  
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5.  Insight in the multidimensional aspects of pain with the Short-form McGill Pain 
Questionnaire74. To measure sensory, affective, and evaluative qualities of pain the 
McGill Pain Questionnaire Dutch version (MPQ-DV) will be used75. 
6.  Performance status of patients will be measured with the Karnofsky scale76. It is based on 
the assessment by the oncologist of the patient` s ability to perform usual daily activities. 
7.  We will identify neuropathic pain characteristics by using the two first questions of 
the Douleur Neuropathic 4 questionnaire, short form (DN4-SF)77. 
8.  To assess multidimensional problems (work, family, et al.) related to cancer the distress 
thermometer (DT) will be used78.
9.  Prevalence of anxiety and depression will be measured with the Hospital Anxiety 
Depression Scale HADS79.
10.  Patients`  experiences with the SMS-IVR system will be assessed with semi-structured 
interviews. 
11.  Self-efficacy for communicating about pain with oncologists will be assessed with 
the mean response to the five items in the Perceived Efficacy in Patient-Physician 
Interactions scale (PEPPI-5), with the wording of the items modified to refer to 
communication about pain with oncologists (Table 1)80.
Sample size 
Sample size calculations of the present study with three clusters of two hospitals, are 
based on the expected effect of the intervention on the PMI. However, the present study 
is the first investigating the effects of using an SMS-IVR system in cancer pain management. 
Several studies show that adequate pain relief can be achieved in 70 to 90% of patients with 
cancer44-47. To achieve this, the present study aims to find out whether our implementation 
strategy reduces the negative PMI from 42%6 to 20%44-47 of all patients with cancer 
visiting the outpatient clinic. To detect a difference with 80% power (alpha = 0.05), we 
need 90 patients per condition. 
 Accounting for clustering resulted in an intraclass correlation coefficient (ICC) of 0.05. 
Based on the ICC and three hospitals per condition, we need 30 patients per hospital. Taking 
into account a dropout rate of 15%, we need 35 patients per hospital, for a total of 210 patients. 
Cluster randomisation of clinics
Clusters of hospitals will be determined based on number of beds and number of medical 
oncologists to increase comparability of hospitals and to reduce contamination64. Of each 
pair, one hospital will be randomly allocated to the intervention condition and the other 
to the control condition. Randomisation took place after all hospital boards and medical 
oncologists had agreed to participate. Next, an independent statistician allocated to the 
intervention or control condition based on clusters by selecting three closed envelopes 
(Figure 1). Patients will be invited to take part by their medical oncologist or research nurse.
Outcomes and measurement instruments
The primary outcomes of this implementation study include: the first primary outcome is 
the percentage of all patients that visits the medical oncology outpatient clinic with 
adequate pain therapy/medication. Pain treatment adequacy will be calculated with both 
the Cleeland’s Pain Management Index (PMI)68 and Ward’s variation of the PMI33. It is the 
most used measure for adequate pain treatment33.  Cleeland’s PMI compares the most 
potent analgesic prescribed, with patient’s reported worst pain level on the Brief Pain 
Inventory (BPI). 
 In addition, Ward’s variation of the PMI compares the most potent analgesic used by 
a patient with that patient’s reported worst level of pain on the BPI. 
 The worst score on the BPI will be determined (1 to 3, mild pain; 5 to 6, moderate pain; 
and 7 to 10, severe pain), where the absence of pain will be defined as 0, mild pain as 1, 
moderate pain as 2 and severe pain as 3. The worst pain score on the BPI is used because 
it is often used clinically as an indicator for treatment69. PMIs will be computed by 
subtracting the pain level from the analgesic level, ranging from -3 (a patient with severe 
pain receiving or using no analgesic drug) to +3 (a patient with no pain receiving or using 
a strong opioid or equivalent). PMI-scores of 0 or higher are considered to be a reflection 
of adequate pain treatment, whereas negative PMI-scores are considered to reflect 
inadequate pain treatment. 
 The second primary outcome is the mean pain intensity of  patients with cancer, 
measured with an NRS (SMS alerts and pain diary). The NRS is the most appropriate choice 
to use in practice for pain intensity (see Table 1)70,71. The pain diary is used to obtain 
additional information (medication use, side effects of medication) and to report pain 
intensity in the control group. 
The secondary outcomes of this study include: 
1.  Percentage of medical records in which pain of new patients in the outpatient oncology 
clinic is registered with a validated instrument, such as the NRS or visual analogical scale 
(VAS). These data will be collected retrospectively via medical records. 
2.  Quality of life of patients assessed with The European Organization for Research and 
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) questionnaire72. 
3.  Knowledge of medical oncologists and nurses of the content of the guideline with a 
self-developed and pilot-tested knowledge questionnaire and vignette study. This 
knowledge questionnaire and vignette study are based on the recommendations in 
the guideline, with input from specialists in pain treatment and GPs. 
4.  Pain intensity and impact of pain on daily activities will be measured with the Brief 
Pain Inventory Short Form (BPI-SF)73. This questionnaire consists of four questions in 
which pain intensity is rated on an 11-point numerical scale (NRS) from 0 (no pain) to 
10 (worst pain ever). 
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Qualitative data collection 
Many studies explored barriers in pain management of patients with cancer and 
professional caregivers in different countries. However, this has never been done in the 
Netherlands. Therefore, four focus group interviews will take place to explore barriers and 
incentives about cancer pain management with respectively: patients with cancer, oncologists, 
nurses and GPs. Focus groups offer an opportunity to obtain significant insight regarding 
the experiences, observations, and opinions of members of that group81.
In addition, semi-structured interviews by phone focused on patient empowerment will 
be used to evaluate the SMS-IVR intervention. 
 Ten randomly selected participating patients per hospital will be interviewed. The aim of 
these interviews is to shed light on the results of the intervention and the effect on patient 
empowerment. 
Retrospective analysis
To investigate how and how frequently pain has been reported in medical records 
retrospective analysis will be performed for the year 2010 (two years after the guideline 
has been published). Thirty-six medical records per hospital (the first three of each month) 
of oncology patients who came for their first consultation at the outpatient clinic will be 
obtained. Retrospective analysis of medical records will be repeated after the intervention 
period. 
Additional data 
Data on patients characteristics will be obtained from medical records: patient identification 
code, date of diagnosis, gender, age, postal code, marital status, primary cancer type, 
secondary cancer, history of cancer treatment, present treatment, cancer exact location, 
TNM stage cancer, and pain medication. Retrospective data of surgery and other cancer 
treatment during intervention period, and hospital admission(s) (number, length and 
indication) will also be analysed.  
 Other data will be obtained via a patient questionnaire including questions about: 
SMS use, education level, and experiences with present pain treatment. 
Ethical considerations 
The study has been approved by the Medical Ethics Committee (CMO) of the Radboud 
University Nijmegen Medical Centre (METC protocol number 2011/020). The Dutch Cancer 
Society (KWF) approved the research protocol, which has been registered by the Dutch 
Trial Register (NTR2739). This study has also been registered by the local ethical committees of 
each hospital. Anonymity of every patient is guaranteed. Patients have to sign an informed 
consent before start of the intervention. 
Statistical analysis 
To measure the effect of the implementation the PMI and NRS will be used and tested 
with general linear model analysis of variances (GLM ANOVA) repeated measures. 
Qualitative content analysis will be used to analyse the results of the focus group 
discussions and to analyse the interviews to evaluate the SMS alert intervention. Qualitative 
analysis will be supported by the use of the Atlas.ti software programme. 
 Data collected via SMS-IVR will be analysed for descriptive data: how did pain scores 
change and fluctuate in the whole period, what actions were taken by the research nurse, 
and did this intervention help the patients to manage pain? Subgroup analysis will be 
conducted. Differences in subgroups of the effectiveness of the intervention are expected. 
Subgroups will be classified by: age, gender, race, education, performance status, and 
classification of malignant tumours (TNM stage). The most recent version of SPSS will be 
used to perform the statistical analysis. 
Table 1  Patient questionnaires/scales
Measurement Validated questionnaires Time points (M=month)
Pain intensity A. Numeric Rating Scale (NRS)
B. Brief Pain Inventory Short form 
(BP-SF)
A. M0-M3/ M9/ M15
B. M0/M3/ M9/ M15
Multidimensional aspects 
of pain
McGill pain questionnaire (MPQ) M0/M3/M9/ M15
Pain interference with 
function
Brief Pain Inventory Short form  
(BP-SF)
M0/M3/M9/ M15
Adequate pain treatment Ward`s Pain Management Index 
(PMI-revised)
M0/M3/M9/ M15
Quality of life European Organization for Research 
and Treatment of cancer Quality  
of Life Questionnaire- C30 (EORTC 
QLQC30)
M0/M3/M9/ M15
Neuropathic pain Neuropathic Pain Diagnostic 
Questionnaire (DN4-SF) (first two 
questions)
M0/M3/M9/ M15
Problems in daily life 
associated with cancer
Distress Thermometer (DT) M0/M3/M9/ M15
Emotions related to cancer Hospital Anxiety and Depression 
Scale (HADS)
M0/M3/M9/ M15
Performance status Karnofsky Performance Scale (KPS) M0/M3
Self-efficacy for 
communication about  
pain with oncologist
Perceived Efficacy in Patient-
Physician Interactions (PEPPI-5)
M0/ M3
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 Apart from the SMS-IVR, a pain diary is necessary to obtain data on pain intensity in 
the control group and additional information in both control and intervention group. 
 Asking about pain by measuring pain intensity with a pain diary in itself can reduce pain 
intensity84. Therefore, we expect that pain intensity difference between the intervention 
and the control group will be smaller. However, the possibility of earlier treatment is 
restricted to the intervention group. 
 We expect an increase in motivation of patients to take part in the control condition 
and higher compliance during the study than without the pain diary. However, because 
patients are expected to be more motivated to participate when SMS alerts are offered to 
them, this may cause selection bias. However, it was not possible to randomise at patient 
level, because of the multifaceted intervention. Oncologists and nurses should be trained 
before inclusion of patients. 
 This study protocol shows that the present study is the first to use SMS alerts as a 
reminder in patients with cancer and mobile phones with IVR to collect data on cancer 
pain. Furthermore, this study is innovative in the active involvement of oncologists, nurses, 
GPs, and patients with cancer from guideline development to the implementation of the 
guideline. If the implementation proves to be effective, it can be considered for use in 
other hospitals to increase percentage of patients with cancer that receive adequate pain 
therapy and to reduce pain intensity in patients with cancer. If SMS-IVR proves to be an 
acceptable and useful method to report pain for patients with cancer and medical 
professionals, it can be considered for use of data collection to report pain. Therefore, the 
SMS alert intervention increase patient participation and may increase the feeling of 
having control over one`s life. In this way the SMS alert intervention may encourage pa-
tient-empowerment. 
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Discussion 
This implementation study will be the first RCT to study the use of SMS- IVR to collect data 
on cancer pain. Furthermore, this study is innovative in the active involvement of 
oncologists, nurses, GPs, and patients with cancer from guideline development to the 
implementation of the guideline. SMS and/or IVR have never been used before to assess 
pain in patients with cancer. Using SMS-IVR as a reminder and as a tool to collect data on 
pain scores is an innovative and promising method55. It does not interfere with the 
patient’s daily activities, because SMS has become part of daily life59. Pain can be measured 
systematically at any location with SMS-IVR, the patient can prepare himself (reminder 
before the actual call), can grade his pain two times a day without much effort and time 
investment, and, if necessary, can be treated earlier than in usual care.
 The use of SMS alerts and mobile phones in the present study may be a way to 
encourage patient empowerment, because the patient’s role in their pain management 
becomes more active. Another way to describe this is that it may increase patient 
participation. 
Whether the use of SMS alerts and mobile phones with IVR to report pain in patients with 
cancer may increase patient empowerment or patient participation can be questioned. 
Patient empowerment is a commonly used term within healthcare, but there is little 
consensus regarding its definition.82 In this intervention, the patient is not able to report 
pain at any time. However, the SMS alert may increase the feeling of having control. 
Therefore, the SMS alert intervention increases patient-participation and may increase the 
feeling of having control over one`s life. In this way the SMS alert intervention may 
encourage patient empowerment. 
 In addition, our study will show possible barriers in SMS-IVR use for pain reporting in 
patients with cancer. This has never been done before. One of the possible barriers 
accounted for in the present study is asking too often about cancer pain and this could be 
experienced as a confrontation with their disease. 
 However, nothing is known about a proper frequency to ask patients about their pain 
with IVR. In the present study, patients will receive a weekly SMS alert twice a day. In the 
pilot study, patients received SMS alerts four times a week for four weeks. To achieve a 
similar response rate and compliance as was achieved in the pilot study, the frequency of 
SMS alerts has been reduced in the present study. It has been reduced to once a week if 
there is no pain and to maximal three times a week if pain remains present because the 
intervention period is three times as long. Asking patients about pain improves insight in 
pain intensity of professionals and it increases registration of pain83,84. Asking about pain 
in itself can reduce pain intensity84. Therefore, using SMS-IVR as a way to systematically 
measure pain is expected to reduce pain intensity. 
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Introduction 
In our aging society, cancer prevalence is steadily on the rise. In 2012, the 10-year prevalence of 
cancer in the Netherlands was 454,388, with 101,864  patients newly diagnosed; in 2013, 
the 10-year prevalence was 468,939, with 101,848 patients newly diagnosed1. Trends from 
1989 to 2011 show an average annual increase in incidence of 3%2.
 Pain is one of the most prevalent symptoms of patients with cancer3, with a prevalence 
ranging from 27%4 to 60%5. Undertreatment of cancer pain is associated with anxiety, 
depression, and sleep disturbances6,7; it hampers daily activities8, and therefore affects 
the quality of life. The aim of pain treatment is to reduce pain intensity to an acceptable 
level with minimal side-effects9. Despite the availability of evidence-based clinical practice 
guidelines (CPGs), pain treatment in patients with cancer is still inadequate in 31%10 to 
65%4 of the patients, whereas adequate pain relief is considered feasible in 71%11 to 86%12 
of the patients. The Pain Management Index (PMI) considers pain treatment to be 
adequate if there is congruence between the patient`s reported level of worst pain and 
the prescribed analgesics13.
 The Dutch CPG “Pain in patients with cancer”, developed in 2008, is one of the most 
recent guidelines on this subject in Europe14. However, publishing a guideline alone is 
insufficient15; an implementation strategy is also needed. This strategy should address 
patient and physician related barriers in cancer pain management. Key barriers in pain 
management are the reluctance of many patients to discuss pain with their doctor or to 
ask for pain medication, and the absence of systematic assessment and registration of 
pain by medical professionals16.
 A promising method for lowering these barriers is pain monitoring using interactive 
voice response (IVR) with short message service (SMS)-alerts. 
 IVR/SMS enables patients to communicate with health care professionals outside the 
consultation room. Patients hear a recorded message on their phone and respond to 
queries using their keypad. SMS-alerts are text messages used to alert health professionals 
when symptom scores need follow-up. SMS-alerts have been successfully used for 
collecting weekly symptom data, and have been shown to  improve health outcomes in 
patients with asthma17, irritable bowel syndrome18, and diabetes19. 
 A pilot test using IVR-SMS alerts to collect prospective and follow-up data on pain 
intensity in patients with cancer gave positive results and was considered acceptable20. 
These results encouraged us to set up a study to assess the effect of using the interactive 
distance alert system (MIDAS 4 Cancer Pain) to monitor a possible reduction in the 
percentage of patients with a negative Pain Management Index (PMI). We hypothesized 
that the MIDAS 4 Cancer Pain treatment would be more effective in reducing the 
percentage of patients with a negative PMI than usual care. In addition, we expect that 
patients with moderate to severe pain (NRS 5-10) at baseline would benefit most from the 
MIDAS 4 Cancer Pain intervention.  
Abstract 
Background. Cancer pain is still undertreated in more than 50% of the patients. We 
monitored patients to assess the effect using the interactive distance alert system (MIDAS 
4 Cancer Pain) on the reduction of the percentage of inadequate cancer pain treatment. 
Methods. In a cluster randomised controlled trial, eight hospitals were randomly assigned 
to the MIDAS 4 Cancer Pain (M) or control (C) groups (4:4). Primary outcome was the Pain 
Management Index (PMI) at week 12. Secondary outcomes included pain intensity, 
interference with daily activities, neuropathic pain characteristics, pain descriptors, quality 
of life, emotional distress, and self-efficacy regarding communication about pain. Results. 
111 patients with cancer and pain participated in this study (M 72: C 39). At week 12, the 
percentage of patients with a negative PMI in the MIDAS 4 Cancer Pain group was not 
significantly lower than in the control group (16%; 95%CI -3 to 35; P=0.12). Pain-related 
interference with daily activities and depressed mood score were significantly lower in the 
MIDAS 4 Cancer Pain group. In the subgroup of patients with moderate to severe pain 
(NRS 5-10) at baseline, the percentage of patients with a negative PMI was significantly 
lower in the MIDAS 4 Cancer Pain than in the control group (35%; 95% CI 7 to 62; p=0.03). 
Conclusion. The reduction in inadequate pain treatment was not significantly higher in 
the total group of patients compared to controls. Results for the subgroup of patients with 
moderate to severe pain revealed that the intervention was significantly more effective in 
reducing inadequate pain treatment. Our data are therefore promising when defining 
subgroups for which the intervention might be effective. In addition, our results demonstrate 
the positive effects of Midas 4 Cancer Pain on pain-related interference with daily activities 
and depressed mood. 
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drug therapy actually used and the patient’s worst pain level. The levels of analgesic 
treatment are scored as 0, no analgesic; 1 a non-opioid analgesic; 2 a weak opioid; and 3 a 
strong opioid. The levels of worst pain are scored as 0, absence of pain; 1, mild pain; 2, 
moderate pain; and 3, severe pain. The PMI score is determined by subtracting the pain 
level from the analgesic level and can range from -3 to +3. 
Pain- related secondary outcomes
Pain- related outcomes were assessed in 5 ways: 1)Pain intensity using the Brief Pain 
Inventory Short Form (BPI-SF); 2) neuropathic pain characteristics (≥ 3 out of 7) (NPC) with 
the Douleur Neuropathic 4 questionnaire short form (DN4-SF); 3) the pain severity index 
was calculated as the sum of worst pain, least pain, average pain, obtained from the BPI-SF; 4) 
pain-related interference with daily activities using the BPI-SF; and 5) pain descriptors were 
obtained from the short- form McGill Pain Questionnaire (MPQ) (references see appendix).
Quality of life related secondary outcomes
Quality of life(QoL) related secondary outcomes were assessed in 4 ways: 1) QoL was 
assessed using the European Organization for Research and Treatment of Cancer Care 
Quality of life Questionnaire (EORTC QLQ-C30); 2) anxiety and depression scores were 
measured with the Hospital Anxiety Depression Scale (HADS); 3) self-efficacy for 
communicating about pain with the medical oncologist using the Perceived Efficacy in 
Patient-Physician Interactions scale (PEPPI-5) and 4) experiences of patients with the 
MIDAS 4 Cancer Pain intervention were collected. (references see appendix)
Statistical methods
The power calculation, as reported in our protocol21, was updated based on new insights28. 
We aimed to reduce the percentage of patients with a negative PMI at week 12 to 20% in 
the MIDAS 4 Cancer Pain group compared  to 62%28 in the control group. Twenty-four 
patients are needed in each group to obtain a power of 80%, using a Fisher-exact test 
(two-sided alpha =0.05). To account for clustering (ICC = 0.05) and to allow for an additional 
dropout rate of 15%, 39 patients in each group were needed in our study. 
 Descriptive statistics were used to present patient characteristics in each group. The 
Fisher exact test was used to test the difference in the primary outcome (PMI < 0) at week 
12 between the intervention and control groups. 
 As patients with moderate to severe pain (NRS 5-10) at baseline would benefit most 
from the MIDAS 4 Cancer Pain intervention, and as clinical practice guidelines recommend 
treating this subgroup of patients14, we were specifically interested in the effect of the 
MIDAS 4 Cancer Pain treatment in these patients. In addition, in the IVR-SMS-alert 
procedure, nurses only take action for patients that report an NRS ≥ 5. We therefore 
decided to perform a subgroup analysis of patients with an NRS ≥ 5 at time of inclusion. 
The Fisher exact test was also used for all dichotomous secondary outcomes. 
Method
Participants 
We performed a multicenter, cluster randomised controlled trial. The trial protocol, 
approved by the Medical Ethics Committee (protocol number 2011/020), has been 
outlined in a previous study21. All participants provided written informed consent.
 Patients were eligible for inclusion if they had been diagnosed with cancer, were 18 years 
or older, and experienced pain related to cancer or to anti-cancer treatment with an 
intensity of > 0 on a Numeric Rating Scale (NRS).
 In the original protocol patients with a pain intensity of ≥ 3 on an NRS were eligible; 
the protocol amendment to include all patients with pain was approved. Patients with 
severe cognitive disorders and those who were not able to speak or write Dutch were 
excluded (n=0). Figure 1 shows the flow diagram for this study; the RCT follows the 
CONSORT reporting guidelines. 
Randomisation and masking
Eight hospitals were randomised in a 4:4 ratio to the MIDAS 4 Cancer Pain or the control 
group based on hospital size. 
 Departments in these hospitals with an outpatient clinic treating oncology patients 
were asked to participate. Although complete masking of groups was not possible, 
patients were asked to participate in their own study condition without being informed 
of the existence of another condition. Patients were recruited from 16 September 2011 to 
31 December 2014 by health care professionals responsible for cancer care (oncologists, 
urologists, gynaecologists, and nurses).
Procedures
The MIDAS 4 Cancer Pain treatment protocol requires medical professionals to be trained in 
using the guideline ‘pain in patients with cancer’14 and patients’ pain was monitored with IVR-
SMS-alerts. In the control hospitals no training took place, and patients completed a pain diary. 
 In both groups, patients were asked to report pain on an NRS twice daily, once a 
week, for 12 weeks. As part of the MIDAS 4 Cancer Pain treatment, an automatic alert (by 
SMS and email) was sent to the study nurse when a patient reported a pain score of 5 or 
higher. The study nurse then contacted the patient within two hours and, after having 
explored the problem, advised the patient or adjusted pain medication. 
 In addition, the study nurse activated IVR and SMS-alerts for the next two days to 
monitor the clinical impact of the advice or medication change21.
Primary outcome
The primary outcome was defined as a negative PMI13 score suggests inadequate 
analgesic pain treatment13.  The PMI is calculated based on the most potent analgesic 
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At week 12, mean symptom scores related to QoL were significantly lower in the MIDAS 4 
Cancer Pain group than in the control group for nausea and vomiting(14.1; 95% CI 4.5 to 
23.5), appetite loss (20.6; 95% CI 1.6 to 39.7),and financial difficulties (8.3; 95% CI 0.0 to16.6). 
(Table 2)
 In addition, the mean score for depressed mood was significantly lower in the MIDAS 
4 Cancer Pain group than in the control group (2.0; 95% CI 0.1 to 3.8; p=0.04). (Table 2)
 We used linear mixed models with adjustment for baseline values to study the 
influence of the intervention on the continuous secondary outcomes at 12 weeks. The 
dependent variable was the outcome measure of interest. The independent fixed variables 
were group (intervention, control) and the baseline score.
 Hospital was treated as a random variable. We present the baseline adjusted mean 
difference between the groups at 12 weeks with the 95% CI. Analyses were done using 
the principle of intention-to-treat. Statistical analyses were performed using SAS 9.2 for 
Windows and IBM SPSS statistics 20 for Windows. 
Results
Participant characteristics
A total of 111 patients signed the informed consent form; 72 were placed in the MIDAS 4 
Cancer Pain group (M) and 39 in the control group (C). Of the original 111 patients, 62 and 
29 per group respectively completed the baseline measurements. (Figure 1, Table 1) 
Table 1 presents the patient demographics. In the MIDAS 4 Cancer Pain group, less men 
(MIDAS 50.0%: Control 65.5%) and less patients with lung tumours participated (MIDAS 
4.8%: Control 20.7%) than in the control group. Gastrointestinal tumours were more common 
in the MIDAS 4 Cancer Pain group (MIDAS 30.6%: Control 13.8%) compared to the control 
group. In addition, 91.7% of the patients underwent palliative care in the MIDAS 4 Cancer 
Pain group, and 75.0% in the control group. 
Response rate to IVR calls
The response rate to the IVR calls was 1334 of the 1398 calls (95.4%). Of these responses, 1029 
(77.1%) were correct. Incorrect responses were caused by technical requirements of the system 
used. The hash symbol needed to switch from the introduction section to the question, 
resulted in incorrect use of the system in 288 of the 1398 IVR calls (20.6%); in these cases the 
call was disconnected, and in 17 of the 1398 IVR calls (1.2%) the system did not  function. 
Primary outcome: negative PMI at week 12 
Data of 60 and 28 patients for the M and C groups respectively were analysed for primary 
outcome. At week 12, the percentage of patients with a negative PMI in the MIDAS 4 
Cancer Pain group was not significantly lower than in the control group(16%; 95%CI -3 to 
35; P=0.12).(Table 2) 
Pain- related secondary outcome
Mean pain- related interference with daily activities in the MIDAS 4 Cancer Pain group was 
significantly lower than in the control group at week 12 (7.9; 95% CI 1.0 to 14.9; p=0.03).
(Table 2)
Figure 1   Flow diagram 
Patients assessed at 
week 12: Patients who  
dropout (n=3); patients  
who completed the 
intervention (n=36) 
Dropout: too ill, too much
work (n= 7); died before
start (n= 1); progression
disease (n=1); progression
disease and does not want
to work with SMS-IVR
(n=1)        
 
Dropout: hospital
admission (n=1); to avoid
confusion (n=1); pain gone
(n=2); unknown (n=1)       
 
 Dropout: died (n= 3);
hospital admission (n=1);
too ill, too tired to
complete questionnaire
(n=3); unknown (n=7)    
Patients assessed at  
week 12: Patients who  
dropout (n=2); patients 
who completed the 
intervention (n=25) 
Dropout: too ill (n= 3);  
died before start (n= 3);  
unknown (n=2);   
problems at home; (n=1);   
CVA (n=1)
Dropout: progression  
disease (n=1);  (n=1)  
unknown 
Dropout: pain gone (n=1);  
unknown (n=1)  
 
completed control 
treatment (n= 27)  
Completed experimental 
treatment (n= 50) 
 
 
 
Start control treatment
 (n= 29) 
 
 
Start experimental
treatment (n= 62)   
 
 
Patients included
 (n= 39)
 Patients who completed
baseline measure (n= 72) 
Sites allocated to control
treatment (n= 4) 
Sites randomised (n=8) 
Sites allocated to
MIDAS 4 Cancer Pain
treatment (n= 4)   
Dropout: died (n= 7)  
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Table 1  Demographics of the participants
 MIDAS 4 Cancer  
Pain group
n=62
Control group
n=29
Median  
or n/N 
(IQR)  
or (%)
Median  
or n/N 
(IQR)  
or (%)
Individual level 
Age (years) 63.0 (56.8-68.0) 64.0 (54.0-72.0)
Male 31/62 (50.0) 19/29 (65.5)
Education level
Secondary school or less  19/61 (31.1) 11/29 (37.9)
Lower vocational education  11/61 (18.0)   2/29 (6.9)
Middle vocational education  22/61 (36.1)   8/29 (27.6)
Higher professional education/ academic    9/61 (14.8)   8/29 (27.6)
Tumour type a 
Head and neck   1/62 (1.6)   0/29 (0.0)
Gastrointestinal 19/62 (30.6)   4/29 (13.8)
Lung   3/62 (4.8)   6/29 (20.7)
Breast 17/62 (27.4) 10/29 (34.5)
Prostate 13/62 (21.0)   7/29 (24.1)
Urogenital other   2/62 (3.2)   2/29 (6.9)
Gynaecological   4/62 (6.5)   0/29 (0.0)
Haematological   1/62 (1.6)   0/29 (0.0)
Other   1/62 (1.6)   0/29 (0.0)
Unknown tumour   1/62 (1.6)   0/29 (0.0)
Karnofsky performance scale (%)b 80.0  (70.0-80.0)   80.0 (70.0-90.0)
Treatment type 
Curative   2/60 (3.3)   2/28 (7.1)
(neo-) adjuvant   3/60 (5.0)   5/28 (17.9)
Palliative 55/60 (91.7) 21/28 (75.0)
Cluster levelc Mean Range Mean Range 
Mean number of patients  20.7 (12-35)   7.3 (3-14)
Mean number of male 10.3 (4-19)   4.8 (2-12)
Mean number of patients with palliative care 18.3 (11-33)   5.3 (2-11)
Data are median (IQR) or n/N (%) a Adapted from van den Beuken et al. b Karnofsky performance scale is missing 
in 14 patients in the control group and in 4 in the MIDAS 4 Cancer Pain. c mean (range).
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Patients’ experiences 
Table 3 presents the patient experiences with treatment. The percentage of patients who 
agreed that their pain control improved during treatment was the same for both groups 
(43%). Eight of the 34 patients (23.5%) in the MIDAS 4 Cancer Pain group noted that they 
reported lower NRS scores to avoid  the nurse calling them.
Discussion 
This cluster RCT shows that reduction in inadequate pain treatment was not significantly 
higher in the MIDAS 4 Cancer Pain group than in the control group. Yet, in the subgroup 
of patients with moderate to severe pain at baseline, MIDAS 4 Cancer Pain was significantly 
more effective in reducing inadequate pain treatment. 
 In this subgroup analysis, patients were excluded who had a mild pain intensity at 
baseline as for this group pain treatment could not or hardly improve. 
 Patient recruitment was difficult because of pain related barriers; oncologists do not 
systematically ask patients about their pain and patients are reluctant to talk about their 
pain. Due to these recruitment issues, we adapted the inclusion criteria for pain intensity 
from ≥ 3 on an NRS to ‘all patients with pain’. As a result, patients with mild pain were also 
included which may have resulted in increased medicalization due to the extra focus on 
pain. However, this adaptation also became a strength, as it enabled a subgroup analysis 
to determine who would most benefit from MIDAS 4 Cancer Pain. 
 Although we aimed to include patients in all cancer stages, the majority of our study 
population consisted of palliative patients, particularly in the MIDAS 4 Cancer Pain group. 
This inclusion bias is possibly due to the higher prevalence of pain in patients with an 
advanced disease stage, for whom the treatment focus changes from curative treatment 
to symptom management. This inclusion bias caused a higher number of missing values 
and dropout than expected. 
 Despite recruitment difficulties, most patients in the MIDAS 4 Cancer Pain group 
(77%) considered the total time investment to be acceptable, and an equal percentage 
agreed that the frequency of the IVR calls was acceptable. However, 24% percent of 
patients reported lower NRS scores to avoid  the nurse calling them.
 This shows that to achieve patient-centred care, the need or wish of patients to report 
their pain level or to be contacted by the study nurse should be taken into account. 
 Yet, of those patients that participated in the study, almost all in the MIDAS 4 Cancer 
Pain group adequately responded to the weekly IVR-SMS-alerts (95%). This is in line with 
results from a recent study in which IVR completion rates were also  high25. These figures 
suggest that patients with an advanced stage of cancer are able to use IVR for symptom 
management23,25. 
Subgroup patients with moderate to severe pain 
Findings from the subgroup analysis in patients with moderate to severe pain (NRS 5-10) 
at baseline showed that the percentage of patients with a negative PMI was significantly 
lower in the MIDAS 4 Cancer Pain at week 12 (35%; 95% CI 7 to 62; p=0.03 N=39). 
 In addition, the secondary outcomes in the subgroup showed a significantly higher 
mean PMI score in the MIDAS 4 Cancer Pain group than in the control group (0.8; 95% 
CI 0.21 to 1.29; p=0.01). 
Table 3  Patient experiences with treatment and study design
 MIDAS 4 Cancer 
Pain group
n=35
Control group
n=24
Difference 
between 
groups
n/N (%) n/N (%) P-value
(2-sided)*
My pain control improved
Agreed 14/32 43.8 10/23 43.5 0.98
Did not know 15/32 46.9 3/23 13.0 0.01
Disagreed 3/32 9.4 10/23 43.5 0.00
Time investment was acceptable 
Agreed 27/35 77.1 21/24 87.5 0.50
Did not know 7/35 20.0 1/24 4.2 0.13
Disagreed 1/35 2.9 2/24 8.3 0.56
Frequency of IVR calls or filling in pain 
diary was acceptable 
Agreed 28/35 80.0 20/23 87.0 0.73
Did not know 7/35 20.0 2/23 8.7 0.30
Disagreed 0/35 0.0 1/23 4.3 0.40
I would participate in this study again if 
I were asked 
Agreed 19/30 63.3 12/23 52.2 0.41
Did not know 9/31 29.0 6/23 26.1 0.81
Disagreed 3/30 10.0 5/23 21.7 0.21
I reported lower NRS scores than the 
real pain scores to avoid that the nurse 
would call : Yes
8/34 23.5 n/a - -
*Chi-square or Fischer’s Exact test. 
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Appendix  Secondary outcomes
Pain and pain- related secondary outcomes
1) Brief Pain Inventory Short Form (BPI-SF)1
2) Douleur Neuropathic 4 questionnaire short form (DN4-SF)2
3) Short- form McGill Pain Questionnaire3,4
Quality of life and quality of life-related secondary outcomes
1) European Organization for Research and Treatment of Cancer Care Quality of life 
Questionnaire (EORTC QLQ-C30)5
2) Hospital Anxiety Depression Scale (HADS)6,7 Patients screened positive for anxiety or 
depression with a score of ≥ 8 on a subscale7-9
3) Perceived Efficacy in Patient-Physician Interactions scale (PEPPI-5).10
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Introduction 
In Europe, in 2006 about 3.2 million patients were diagnosed with cancer1  and in 2012 this 
number increased to 3.5 million2. As a result of the ageing population, this number is 
expected to increase further in the next decades1. Pain is one of the most prevalent 
symptoms of patients with cancer; more than 50% of them suffer from it3.  
 Since cancer pain hampers daily activities4, quality of life5-7 and is also associated with 
anxiety, depression and sleep disturbances5-7, cancer pain strongly influences patients’ 
quality of life and wellbeing. Although adequate pain relief up to 86% of patients with 
cancer is considered feasible8, inadequate pain treatment ranged from 31%9 to 65%10. 
Thus, cancer pain is still undertreated. 
 Multi-disciplinary pain management, in which medical, behavioral and cognitive 
aspects are combined, has been found to be more effective than single pharmacological 
treatments11. Patient empowerment could be one of these aspects, as it has been 
highlighted as central to success in pain management12. 
 Since 1988, patient empowerment has gained more attention in healthcare13. The 
European Network on Patient Empowerment (ENOPE 2012), defined patient empowerment 
as “a process to help people gain control, which includes people taking the initiative, 
solving problems, and making decisions”14. Patient empowerment is a growing trend; 
models of patient-doctor relationships are making way for empowered patient models 
with patients as active partner15. The concept empowerment in healthcare might get 
increasing interest in the next decades, because of the requirement to reform healthcare 
systems16. Healthcare systems should deliver healthcare in a way that meets the increasing 
health demands in a cost-effective manner16. An empowered patient probably self-manages 
his cancer pain to a larger extent than a non-empowered patient. 
 Self-management might be an alternative for the traditional patient-physician hierarchy, 
which might increase cost-effectiveness15. 
 Up to now, no clear patient empowerment model exists that can guide cancer pain 
management, although several strategies to empower patients are currently used in 
clinical practice17. Such a model might be useful to implement empowerment in a more 
consistent way in clinical practice. Therefore, this review examines how empowerment or 
related concepts have been described in relation to pain management in patients with 
cancer in order to provide recommendations and to define a conceptual model.
Method
We performed an integrated review. Whittemore and Knafl defined an integrative review 
as ‘a specific review method that summarizes past empirical or theoretical literature to 
provide a more comprehensive understanding of a particular phenomenon or healthcare 
problem’18. As this paper examines how empowerment or related concepts have been 
Abstract 
Background. More than 50% of patients with cancer experience pain. Patient empowerment 
has been highlighted as central to success in pain management. Up to now, no clear 
model for this patient group exists, yet several strategies to empower patients have been 
used in clinical practice. This review examines how empowerment or related concepts 
have been described in relation to pain management in patients with cancer. With the 
help of a conceptual model recommendations for clinical practice are provided. Methods. 
An integrative review was conducted, using the databases PubMed, CINAHL and PsycINFO. 
We evaluated papers discussing empowerment or related concepts in relation to pain 
management in patients with cancer. We analysed the term ‘empowerment’ semantically. 
Results. From a total of 5984 identified papers, 34 were included for analysis. Empowerment 
has been described with the concepts self-efficacy, active patient participation, increasing 
abilities, and control of life. Most papers focus on pain treatment induced by the professional 
caregiver or on the active involvement of the patient, and not on the combination of both. 
The following elements of empowerment could be discriminated: role of the patient, 
role of the professional, resources, self-efficacy and active coping, shared decision- making. 
Conclusions. Based on the findings we propose a conceptual model to empower 
patients in controlling cancer pain. We recommend focusing on pain treatment given by 
the professional, on the active involvement of the patient, and on the interaction of both. 
Our model might also be useful for other patient groups or specific contexts, especially in 
symptom management. 
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Results
Included studies 
We initially identified a total of 5984 articles; 5839 citations by database searching and 145 
citations by hand searching. After correction for duplicates, 4987 citations were reviewed 
on title. The remaining 490 papers after title selection were reviewed on abstract and 155 
papers were selected for full text reading. An assessment of full text excluded 121 papers. 
The remaining 34 papers were 22 studies with empirical data, three case reports, one 
systematic review with meta-analysis, two theoretical papers, two opinion papers, one 
study protocol, two validation studies and finally one invited commentary. The detailed 
selection process is described in Figure 1.
Empowerment in relation to cancer pain management
Seven papers out of 34 described or defined empowerment in pain management in 
patients with cancer. They focused on a limited number of aspects of empowerment in 
pain management (see table 1). Some papers focus on the professional caregiver and 
others on the active involvement of the patient, however both  should be discussed. 
Although Kravitz et al22,23 described their intervention as ‘Cancer Health Empowerment 
for Living without Pain intervention’ (Ca-HELP), they measured and discussed 
empowerment as self-efficacy for pain control and for patient-physician communication. 
Whereas Lasch24 and Thomas25 described empowerment as active patient participation 
in pain management, Tse et. al. 26, McNeill27, González Barón 28 described the empowerment 
concept itself. 
 Lasch24, Thomas25, González Barón28 and McNeill et al. 27 addressed that access to 
resources are essential in empowerment to control pain (e.g. enjoy themselves, plans for 
the future, information, access to support). Tse26 defined empowerment as increasing 
patients abilities to take control of their life and McNeill27 as a feeling of control, making 
patients active participants in pain management. González Barón28 defined empowerment 
as the belief that patients with cancer could do something to feel better by empowering 
resources (enjoy themselves, plans for the future) and that empowering resources of 
patients with cancer and pain might help them to give a new sense to their lives. Both 
Tse26 and McNeill27 note that the feeling of control over their pain can empower patients 
(see table 1).
Related concepts of empowerment
Eighteen out of 34 papers discussed the concept of self-efficacy in pain management. 
Self-efficacy has been well defined and these definitions show strong similarities with the 
descriptions of empowerment in the previously mentioned papers. Self-efficacy has been 
defined in pain management as ‘the patient`s confidence, perception or belief in his or her 
ability to perform a specific behaviour, task or to achieve a desired goal’22,23,29-36.
described, both empirical and theoretical data were needed. Therefore, an integrative 
review based on the guidelines suggested by Whittemore and Knafl was the first choice18.
We evaluated papers discussing empowerment or empowerment-related concepts in 
relation to pain management in patients with cancer. As other constructs, like self-efficacy 
and shared decision-making (SDM), have shown to be essential in cancer pain management19,20 
and also show overlap with empowerment, these were included too. Therefore, to get 
insight in the concept empowerment, related concepts should be taken into account. 
Studies included in this review have varying methodological quality, but all were included 
in this review in accordance with the integrative review approach18. 
Search strategy
Databases PubMed, CINAHL and PsycINFO were searched. Detailed search strategies are 
presented in Appendix 1. The search was limited to studies published between 1990 and 
October 2012.  Studies on children (<18 years of age) were excluded.
 Key words and/or MESH terms used were empowerment, self-efficacy, mastery, self- 
control, self-esteem (obtained from Samoocha et. al21), self-concept, self-perception, internal- 
external control, decision-making and self-regulation. These key words and/or MESH terms 
were combined with pain management, pain measurement, analgesia, pain therapy, pain 
prevention, pain control and pain assessment. The search strategy was not limited to cancer, 
since papers may discuss patients with cancer without mentioning it in the abstract or title. 
 Reference lists of selected publications as well as major relevant journals (Pain, 
 Anaesthesiology, CA: A Cancer Journal for Clinicians, Nature Review Cancer) were hand- 
searched to check for missing publications.
In- and exclusion criteria 
Papers that studied or discussed empowerment or empowerment related concepts in 
relation to pain management or pain management/control were included. Papers were 
excluded when empowerment/ empowerment related concepts or pain management/
control were not related to cancer or were not separately discussed for cancer; when 
empowerment or related concepts were not discussed in relation to pain management/
control; when empowerment or related concepts were only related to professional 
caregivers; when the study population consisted of patients with a psychiatric or cognitive 
disorder/impairment or depression; and finally, when the paper was not written in English. 
Data extraction 
One of the authors (NtB) initially identified and reviewed citations on title. Two authors 
(IL and NtB) independently reviewed the papers remaining after title selection on abstract 
and they selected papers for full text reading. Discrepancies were discussed and a third 
reviewer (YE) was consulted when necessary. Data were extracted on study design and 
descriptions, definitions and theories on empowerment related concepts.  
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 It has been defined as a cognition22,23,29-36, whereas empowerment has been 
described as an action or/and as a cognition (table 1). Self-efficacy is task-specific22,23,29,30. 
Patients with high communication self- efficacy may still have low confidence for 
performing pain self-care behaviors. Others do refer to self-efficacy but do not define or 
describe it37-44.  
 Other related concepts of empowerment discussed are coping strategies and/or 
locus of control, self-esteem and mastery. Although these concepts have been discussed 
in four out of 34 papers51-54 they do not describe or define it. Büssing and authors51 
analysed which coping strategies refer to the concept ‘locus of control’. They found that 
patients with cancer often have a strong reliance on external sources (e.g. trust in God`s 
help). Büssing et al described external resources of control, however they also reported 
internal resources55. These external resources might not be seen as true factors of 
empowerment because they are often used as passive strategies, while the internal strategies 
are in most cases active processes (e.g. abilities).
 Finally, a concept related to locus of control is mastery. Kurtz defined mastery as sense 
of control, as the extent to which a person feels in control over his/her environment56.
Conceptual model to empower patients in controlling cancer pain
Based on these findings, we suggest a conceptual model to empower patients in controlling 
cancer pain. A cyclical model seems most appropriate, as pain and other  characteristics 
might change over time and sometimes the patient and professional caregiver have to start all 
over again to empower the patient. Previous research focussed only on pain treatment 
provided by the clinician or on the active involvement of the patient, but not on the 
combination of both. However, both are essential to empower the patient in controlling 
their cancer pain. Patient empowerment could improve pain management and pain 
control might result in improved empowerment and this might result in more pain control. 
 Therefore, we suggested a model with both the patient as the clinician as well as their 
interaction. Self -efficacy has been shown essential in both elements of empowerment. 
In relation to empowerment it has been described as a core cognition. In this model e.g. 
communication self-efficacy, and self-efficacy for shared decision-making are essential. 
Another essential element of empowerment is having resources.
 A professional caregiver can induce external resources (e.g information on pain 
management, pain treatment) and use strategies to empower the patient. However, the 
patient needs to be involved to become empowered and to manage his pain. External 
and internal resources have been described. Internal resources are related to the patient, 
like his abilities, his attitude. Yet, external resources can be introduced by the professional 
caregiver e.g. information or access to support. Resources and self-efficacy are a prerequisite 
to be able to cope actively. Yet, resources and self-efficacy are not enough to achieve pain 
control. The patient also needs to be involved, needs to become an active patient. 
Figure 1   Search flow diagram: Preferred Reporting Items of Systematic reviews and 
 Meta-Analysis (PRISMA)
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
For more information, visit www.prisma-statement.org.
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The definition of empowerment of ENOPE 2012 is: ‘a process to help people gain control, 
which includes people taking the initiative, solving problems, and making decisions’14. 
This definition includes both the help of the clinician and the active involvement of the 
patient. Strategies to empower the patients are also essential in this model. These 
strategies can be either induced by the professional caregiver (collaboration; shared-deci-
sion making; education/coaching; communication) or induced by the patient (becoming 
a partner in decision-making; choose resources according to his/her needs; ask questions 
and obtains information (communication). 
Discussion 
With the help of an integrative literature review, we examined how empowerment or 
related concepts have been described in relation to pain management in patients with 
cancer, and recommendations on how to improve patient empowerment were made, 
illustrated by a conceptual model. Elements in this two-cycle model, with central roles for 
the patient as well as the clinician, are resources (external and internal), self-efficacy, shared 
decision-making and active patient participation/coping. 
 Our results are in agreement with the definition of empowerment of ENOPE 201214. 
Like in our conceptual model, this definition includes both the help of the professional 
caregiver and the active involvement of the patient. Previous research focussed only on 
pain treatment induced by professional caregiver or active involvement of the patient and 
did not combine these elements.Ta
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Figure 2   A conceptual model to empower patients  in controlling their cancer pain
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symptom and the resources may differ, but the framework of the model stays the same. 
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Conclusion 
Based on the findings we propose a conceptual model to empower patients in controlling 
cancer pain. We recommend focusing on pain treatment induced by the professional, on 
the active involvement of the patient, and on the interaction of both. Both elements are 
needed to empower the patient to control their cancer pain. The model should be tested 
in future research. Our model might also be useful for other patient groups or specific 
contexts, especially in symptom management.
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In the past 40 years adequacy of pain treatment in patients with cancer has not improved1. 
Today, both healthcare professionals and decision makers clearly recognize that patient 
centered care is important2. Telemedicine, bridging as well the time gap as the 
geographical gap between professional caregivers and patients, can support them to 
achieve patient centered care, because it might encourage patients to become a partner 
in their own pain management. 
 Although pain in patients with cancer had already been well studied1,3-5,  pain 
management and strategies to improve adequacy of pain treatment in these patients 
were poorly understood. For those reasons, the objective of this thesis was to increase 
awareness and to provide recommendations for clinical practice to improve cancer 
pain management. 
Pain is still a significant problem in outpatients with cancer
In our cross-sectional study in which 428 medical oncology outpatients participated, pain 
prevalence and interference of pain with daily activities were assessed. More than one 
third of all participants reported pain (39%). Eighty-three patients (20%) had moderate to 
severe pain (NRS 5-10). Analgesic treatment was inadequate in more than half of the 
patients with pain (62%). Interference of pain with daily activities increased with increased 
intensity, yet even 10%-33% of patients suffering mild pain reported high interference 
with daily activities. High current pain intensity and high interference with general daily 
activities predicted moderate to severe pain.
The pain prevalence rates we found fall within the range of earlier studies (27%3 to 60%4) 
and prevalence of pain treatment inadequacy ranged from 31%5to 65%3. 
 As adequate pain relief for up to 86%6 of patients with cancer is considered feasible, 
our results show that pain in patients with cancer is still undertreated.
 In earlier studies, a mild pain intensity in patients with cancer (NRS 1-4), usually not 
treated with opioids, has been shown to hardly interfere with daily activities7,8. However, 
we found that some patients with mild pain (NRS 1-4) and even some patients with an 
NRS 1-2 experienced moderate to severe interference with daily activities. Although Serlin 
and colleagues7 established cut-off points for pain intensity based on its interference with 
daily activities already 18 years ago, there is still no consensus on how to categorize pain 
intensity. Often pain is categorized as mild pain (NRS 1-4), moderate pain (5-6) and severe 
pain (7-10)7,8. Based on our findings we conclude that pain intensity alone is not enough 
to determine whether a patient with cancer and pain needs treatment. Interference of 
pain with daily activities and patients’ needs should also be taken into account(Chapter 2).
Pain is not systematically registered in medical records
In our multicentre retrospective study in which pain registration in medical records of 380 
outpatients with cancer was studied, we found that in 23% of all 987 visits at the outpatient 
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be assessed is not mentioned. Our study was the first to assess medical oncologists`  
intention to act in congruence with an evidence-based cancer pain CPG. 
 An Australian survey among oncologists to identify barriers and facilitators to cancer 
pain assessment and management showed that only 22% of the respondents reported to 
use pain CPGs11. In agreement with our findings, they addressed that particular attention 
should be paid to promoting the use of validated pain assessment scales11 (Chapter 4).
MIDAS 4 Cancer Pain was effective in patients with moderate to severe 
pain in reducing inadequate cancer pain treatment 
We monitored patients to assess the effect using the interactive distance alert system 
(MIDAS 4 Cancer Pain) on the reduction of the percentage of inadequate cancer pain 
treatment. In a cluster randomised controlled trial, eight hospitals were randomly assigned 
to the MIDAS 4 Cancer Pain (M) or control (C) groups (4:4).111 patients with cancer and pain 
participated in this study (M 72: C 39). 
 At week 12, the percentage of patients with a negative PMI in the MIDAS group was 
not significantly lower than in the control group (16%; 95%CI -3 to 35; P=0.12). Pain-related 
interference with daily activities and depressed mood score were significantly lower in the 
MIDAS group. In the subgroup of patients with moderate to severe pain (NRS 5-10) at 
baseline, the percentage of patients with a negative PMI was significantly lower in the 
MIDAS group than in the control group (35%; 95% CI 7 to 62; p=0.03). 
 The reduction in inadequate pain treatment was not significantly higher in the total 
group of patients compared to controls. Results for the subgroup of patients with 
moderate to severe pain revealed that the intervention was significantly more effective in 
reducing inadequate pain treatment. 
 Our data are therefore promising when defining subgroups for which the intervention 
might be effective. In addition, our results demonstrate the positive effects of Midas 4 
Cancer Pain on pain-related interference with daily activities and depressed mood.
 In the subgroup analysis, patients were excluded who had a mild pain intensity at 
baseline as for this group pain treatment could not or hardly improve. Patient recruitment 
was difficult because of pain related barriers; oncologists do not systematically ask patients 
about their pain and patients are reluctant to talk about their pain. Due to these 
recruitment issues, we adapted the inclusion criteria for pain intensity from ≥ 3 on an NRS 
to ‘all patients with pain’. As a result, patients with mild pain were also included which may 
have resulted in increased medicalization due to the extra focus on pain. However, this 
adaptation also became a strength, as it enabled a subgroup analysis to determine who 
would most benefit from MIDAS 4 Cancer Pain. 
Our results are important for health care professionals, patients and future research, as 
they show that MIDAS 4 Cancer Pain has the potential to reduce inadequate pain treatment 
in patients with moderate to severe pain.
clinic, pain or absence of pain was registered, and in an additional 15%, a nonspecific 
symptom description was given(e.g. is doing well, no complaints). Regarding all other 
visits, (62%) pain or absence of pain was not documented at all. Pain measurement using 
a VAS or NRS was documented in only one visit. Pain was more often registered in medical 
records of patients with metastasis, as well as in those of patients with urogenital tumours.
Although pain measurement using a VAS or NRS at each visit is a key recommendation of 
the Dutch CPG on cancer pain, it was documented in only one visit. No recent other data 
on cancer pain registration have been published. In 1999, Weber et al analysed medical 
records of outpatients with cancer and severe pain and found that only three out of 12 
physicians registered pain severity in more than 15% of their consultations9. 
 In our study we did not only analysed medical records of patients known with pain, 
but of all outpatients with cancer. Weber et al analysed the number of physicians 
documenting pain severity, whereas we analysed the percentage of visits in which pain 
was reported, which makes comparing findings of these studies difficult9. Another study 
by Rhodes et al10 found that healthcare providers and healthcare assistants at the radiation 
and medical oncology outpatient clinic did not routinely assess pain10. Additionally, 
Rhodes et al. showed that, before training, physicians never documented quantitative 
pain assessment in their medical records. They found a higher percentage of qualitative 
pain registration in medical and radiation oncology (54% medical and 73% radiation 
oncology vs. 23% in our study)10. We made a distinction between quantitative, qualitative 
and nonspecific symptom registration. Since 2001, pain registration has not improved 
although systemic pain documentation has shown to be feasible in a busy outpatient 
oncology practice and is sustainable over time10 (Chapter 3).
Pain assessment needs more attention in CPGs
In our cross-sectional case vignette survey describing a patient with intractable pancreatic 
cancer and pain, 63 of 268 medical oncologists (24%) completed the survey. Adherence to 
the different recommendations of the guideline ranged from 18 to 100%.
 Confidence for treatment choice ranged from 5.6 to 9.5 on a Numeric Rating Scale 
(0–10). Most of the responding oncologists (94%) adhered to prescribing paracetamol as 
first-line pain treatment, and all prescribed a laxative in combination with opioids to 
prevent constipation. However, only 24% of the respondents adhered to the guideline 
when first-line treatment had insufficient effect. Additionally, only 35% adhered to the 
recommendation for insomnia treatment providing psychosocial support or using a mul-
tidimensional pain questionnaire besides pharmacological treatment. Finally, only 18% 
adhered to the recommendation to perform a multidimensional pain assessment when 
disease worsens and pain increases.
 A possible explanation for this low adherence might be that in the Dutch CPG, the 
recommendations for pain assessment are not specified: when, why and how pain should 
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Almost all patients have a mobile phone or landline telephone and are familiar with its 
use. Finally, in chapter 7 we proposed a conceptual model how to empower patients with 
cancer in pain management based on our integrative review. This model is the first step 
towards patient centered care in cancer pain management, because to become real 
partners in their own care, patients need to be empowered. 
Some limitations of the research should also be considered. One of the prominent 
limitations is that we were not able to obtain characteristics of the non-participants in 
chapter 2 and 6. Another limitation is that in chapter 4, our case-vignette study, the 
response rate was only 24%. Yet, this appeared to be equal to other surveys on cancer pain 
in medical oncologists. This relatively low response rate raises concerns whether the 
results can be generalized to the entire Dutch medical oncologists’ population. The 
responding medical oncologists probably were more interested in cancer pain 
management than non-respondents. For this reason, the low response rate will not have 
influenced our conclusion that pain assessment needs further implementation. 
 A limitation in the study described in chapter 6 is the overrepresentation of palliative 
patients, although we aimed to include patients in our cluster RCT in all cancer stages. This 
inclusion bias might be explained by the higher prevalence of pain in patients in an 
advanced stage of the disease, in which the treatment focus changes from curative to 
symptom management. 
 This inclusion bias increased the number of missing values and dropout as compared 
to what we expected. Secondly, due to recruitment issues, we adapted the inclusion 
criteria for pain intensity from ≥ 3 on an NRS to ‘all patients with pain’. As a result, patients 
with mild pain were also included which may have resulted in increased medicalization 
due to the extra focus on pain. However, this adaptation also became a strength, as it 
enabled a subgroup analysis to determine who would most benefit from MIDAS 4 
Cancer Pain. 
Recommendations for policy makers
This thesis adds that cancer pain management is still a problem, partly due to the lack of 
systematic pain registration and proper pain assessment. In cancer pain management, it is 
not only essential to assess pain but also to register pain. Therefore, in order to facilitate 
pain diagnosis, evaluation and documentation of cancer pain we recommend to 
implement a quality indicator for assessing cancer pain. Although pain physicians often 
like to think of pain management as a human right, organisations generally do not define 
pain management as a specific duty of the physician15. An obligatory quality indicator for 
standardised postoperative pain assessment is already implemented in Dutch practice. 
The need for a cancer pain quality indicator in clinical practice might be as urgent as the 
quality indicator for postoperative pain, because cancer pain management is complicated 
by many barriers. 
Results from a recent multicentre RCT with 253 patients with advanced lung cancer, 
monitoring with IVR and symptom alerts, appeared to be no more effective in reducing 
symptom burden than monitoring alone12. Similar to our study, patients with a low 
symptom burden may have attenuated the effects on the entire group, as they may not 
have required treatment (Chapter 6).  
Conceptual model to empower patients in controlling cancer pain 
Our integrative literature review to examine how empowerment or related concepts have 
been described in relation to pain management in patients with cancer, resulted in a total 
of 5984 identified papers and 34 were included for analysis. Empowerment has been 
described with the concepts self-efficacy, active patient participation, increasing abilities, 
and control of life. Most papers focus on pain treatment induced by the professional 
caregiver or on the active involvement of the patient, and not on the combination of both. 
The following elements of empowerment could be discriminated: role of the patient, role 
of the professional, resources, self-efficacy, active coping, and shared decision making.
We found that empowerment has been poorly defined and described regarding cancer 
pain management. Many other concepts were used to describe empowerment. Self- efficacy 
appeared to be strongly related to empowerment and often used as an empowerment 
outcome. Yet, self-efficacy is needed to achieve empowerment, whereas empowerment 
is not needed for self-efficacy. Our results are in agreement with the definition of 
empowerment of ENOPE 201213.
 Like in our conceptual model, this definition includes both the help of the professional 
caregiver and the active involvement of the patient. Previous research focused only on 
pain treatment induced by professional caregiver or active involvement of the patient and 
did not combine these elements. Only one previously conducted study described a 
limited model of cancer pain management with empowerment as element of the model14 
(Chapter 7).
Methodological considerations 
I will reflect on the strengths and limitations of the methods used in this thesis. One of the 
prominent strengths of this thesis is that the studies described in chapter 2,3,6 were multi- 
centre, including as well academic as peripheral hospitals, which increases generalizability. 
 In addition, in these chapters all patients with cancer (and cancer-related pain in 
chapter 6) were invited to participate, there was no selection on tumour type or disease 
stage. In chapter 4 and 6 medical oncologists were involved. They play a key role in 
planning, delivering, and coordinating cancer care and pain management in these 
patients. Another prominent strength in this thesis is that we tested a telemedicine tool 
that allows patients to communicate with clinicians outside the consultation without time 
delay and irrespective of distance, using a mobile phone or landline telephone in chapter 6. 
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 Another consideration for daily practice might be shifting the responsibility for pain 
management of the oncologist to another profession e.g. the nurse. Finally, we would 
recommend to use IVR and SMS-alerts to monitor pain in patients with cancer and moderate 
to severe pain (see box 1). 
Recommendations for future research
As described in chapter 6, telemedicine can support caregivers and patients to achieve 
patient centred care, because it might encourage patients to become a partner in their 
own pain management. As shown in this thesis pain monitoring with IVR-SMS in patients 
with cancer is feasible and it reduced inadequate pain treatment in patients with moderate 
to severe pain compared to the pain diary. IVR in combination with SMS-alerts might be 
suitable for more symptoms besides pain. Therefore, it would be interesting in future 
research to monitor more symptoms related to cancer or cancer related treatment.  
 Other recommendations for future research are based on our recruitment difficulties 
in the RCT. The effect of the protocol amendments on patient recruitment was small. 
 Besides, it resulted in the inclusion of patients that already had a low pain intensity at 
baseline, and consequently their pain treatment could not improve. Because IVR-SMS was 
effective in those patients with moderate to severe pain (NRS 5-10) we recommend future 
studies to only include patients with moderate to severe pain as they benefit the most 
from the intervention (chapter 6). 
As 24% of patients in the IVR-SMS condition reported lower NRS scores than was really the 
case to avoid that the nurse would call them, personal needs of patients should be taken 
into account in future research. Not all patients might experience a pain intensity of ≥ 5 as 
unacceptable. Therefore, to achieve patient-centred care it might be interesting to assess 
whether or not patients experience their pain intensity as acceptable (chapter 6). 
Patients need to be empowered to become real partners in their own care. In chapter 7, 
we describe a conceptual model to empower patients in controlling their cancer pain. 
This model might be useful to meet the requirements of future care with increasing 
demands in a cost-effective manner. An empowered patient probably self-manages his 
cancer pain to a larger extent than a non-empowered patient. This might improve cost- 
effectiveness. Patients who ask questions, express concerns, and state preferences about 
pain-related matters can change pain management, which in turn may lead to better pain 
control. The next step would be testing our conceptual model to empower patients in 
controlling cancer pain. As well professionals involved in cancer pain management as 
patients with cancer and pain should be involved in such a pilot (see box 1). 
An obligatory quality indicator might help to overcome a few of these barriers. In addition, 
we would recommend to include in the revised version of the CPG pain in patients with 
cancer, clear recommendations for pain assessment and registration; how pain should be 
assessed and registered and who is responsible should be specified. Finally, to facilitate 
assessment and registration of pain with a validated pain assessment scale, we recommend 
to give it more attention in education for medical and nursing students and for 
professionals (see box 1). 
Recommendations for practice 
The findings of this thesis have important implications for daily practice. Because patients 
with cancer are reluctant to talk about pain, we would recommend health professionals to 
systematically assess and register pain in oncology outpatients at each visit with a validated 
pain assessment scale (VAS/NRS). Using pain-specific questions might help patients to 
talk about pain. General questions as “how are you doing?” might not be useful, because 
patients are reluctant to report pain. In addition, we recommend to document also 
absence of pain to facilitate evaluation of pain treatment.  
Box 1 Recommendations/considerations 
Policy makers
3. Implement a quality indicator for assessing cancer pain.
4. Include clear recommendations for pain assessment and registration in the 
 revised version of the CPG for cancer pain. 
5. Invest in the development and improvement of pain educational programs for 
 medical and nursing students and for professionals. 
Practice 
1. Assess and register pain in patients with cancer each visit with a validated pain 
 assessment scale (VAS/NRS).
2. Use pain-specific questions, because patients are reluctant to report pain.  
3. Document also the absence of pain to facilitate evaluation of pain treatment.  
4. Use IVR and SMS-alerts to monitor pain in patients with cancer and moderate  
to severe pain. 
Future research
1. Only include patients with moderate to severe pain in future research using IVR  
and SMS-alerts to report pain as they benefit most. 
2. Personal needs of patients should be taken into account in future research.  
Not all patients might experience a pain intensity of ≥ 5 as unacceptable. 
3. Test our conceptual model to empower patients in controlling cancer pain.  
As well professionals involved in cancer pain management as patients with  
cancer and pain should be involved in such a pilot. 
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General conclusion 
Adequacy of pain treatment in patients with cancer at the outpatient clinic has not improved, 
partly due to the lack of systematic pain registration and proper pain assessment. Today, 
both healthcare professionals and administrators clearly recognize that patient centered 
care is important. 
 As shown in this thesis pain monitoring with IVR-SMS in patients with cancer is 
feasible and reduces inadequate pain treatment in patients with moderate to severe pain. 
It facilitates systematic pain assessment and registration with a validated pain assessment 
scale and supports caregivers and patients to achieve patient centered care.  
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Summary 
In this thesis we monitored patients to assess the effect using the interactive distance alert 
system on the reduction of inadequate cancer pain treatment, we discussed active involvement 
of the patient with cancer in their own pain management and provided recommendations 
for current practice. The overall objective was to increase awareness and to provide 
 recommendations for clinical practice to improve cancer pain management. Firstly, 
we assessed pain prevalence, pain intensity, its interference with daily activities and the 
adequacy of analgesic pain treatment in patients with cancer at the outpatient clinic. 
Secondly, we explored pain registration in medical records of these patients by medical 
oncologists. Thirdly, we assessed medical oncologists`  reported adherence to evidence- 
based guidelines in cancer pain management. Fourthly, we monitored patients to assess 
the effect using the interactive distance alert system on the reduction of inadequate 
cancer pain treatment. Finally, we examined how empowerment or related concepts have 
been described in relation to pain management in patients with cancer. 
In chapter 1, we provided the background of this thesis with epidemiologic data, definitions, 
the role of clinical practice guidelines, the theoretical background, the rationale for the 
use of IVR and SMS-alerts to monitor pain and finally, the outline of this thesis. 
In chapter 2, we describe a cross-sectional study in which 428 medical oncology 
outpatients participated. Pain prevalence and pain-related interference with daily activities 
were assessed using the Brief Pain Inventory questionnaire. 
 Adequacy of analgesic treatment was determined by calculating the Pain Management 
Index (PMI). More than one third of all participants reported pain (39%). Eighty-three 
patients (20% of all) had moderate to severe pain (NRS 5-10). Analgesic treatment was 
inadequate in more than half of the patients with pain (62%). Pain-related Interference 
with daily activities increased with increased intensity, yet even 10%-33% of patients 
suffering mild pain reported high interference with daily activities. 
 Based on our findings we conclude that pain remains a significant problem in medical 
oncology outpatients, and often pain is insufficiently managed. Patients with a high pain 
intensity were more at risk to experience pain related interference with daily activities, but 
even quite some patients suffering from only mild pain, experienced high interference 
with daily activities. As adequate pain relief is considered feasible in 86% of patients with 
cancer, pain in medical oncology outpatients is still undertreated. Taking into account 
pain-related interference with daily activities and predictors of pain will facilitate cancer 
pain management.
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MIDAS 4 Cancer Pain may serve as a tool to support self-management of patients. 
In chapter 6, we reported the results of a clustered randomised controlled trial. We 
monitored patients to assess the effect using the interactive distance alert system (MIDAS 
4 Cancer Pain) on the reduction of the percentage of inadequate cancer pain treatment. 
In this cluster randomised controlled trial, eight hospitals were randomly assigned to the 
MIDAS 4 Cancer Pain (M) or control (C) groups (4:4). Primary outcome was the Pain 
Management Index (PMI) at week 12. Secondary outcomes included pain intensity, 
pain-related interference with daily activities, neuropathic pain characteristics, pain 
descriptors, quality of life, emotional distress, and self-efficacy regarding communication 
about pain. Hundred-eleven patients with cancer and pain participated in this study (M 
72: C 39). At week 12, the percentage of patients with a negative PMI in the MIDAS group 
was not significantly lower than in the control group (16%; 95%CI -3 to 35; P=0.12). 
Pain-related interference with daily activities and depressed mood score were significantly 
lower in the MIDAS group. 
In the subgroup of patients with moderate to severe pain (NRS 5-10) at baseline, the 
percentage of patients with a negative PMI was significantly lower in the MIDAS group 
than in the control group (35%; 95% CI 7 to 62; p=0.03). 
 The reduction in inadequate pain treatment was not significantly higher in the total 
group of patients compared to controls. Results for the subgroup of patients with 
moderate to severe pain revealed that the intervention was significantly more effective in 
reducing inadequate pain treatment. Our data are therefore promising when defining 
subgroups for which the intervention might be effective. In addition, our results 
demonstrated the positive effects of Midas 4 Cancer Pain on pain-related interference 
with daily activities and depressed mood.
Our integrative literature review to examine how empowerment or related concepts have 
been described in relation to pain management in patients with cancer has been described in 
chapter 7. We used the databases PubMed, CINAHL and PsycINFO. We evaluated papers 
discussing empowerment or related concepts in relation to pain management in patients 
with cancer. 
 We analysed the term “empowerment” semantically. From a total of 5984 identified 
papers, 34 were included for analysis. Empowerment has been described with the 
concepts self-efficacy, active patient participation, increasing abilities, and control of life. 
Most papers focus on pain treatment induced by the professional caregiver or on the active 
involvement of the patient, and not on the combination of both. The following elements 
of empowerment could be discriminated: role of the patient, role of the professional, 
resources, self-efficacy and active coping, and shared decision-making. Based on the 
findings we propose a conceptual model to empower patients in controlling cancer pain. 
In chapter 3, we described the results of a multi-centre study in six Dutch hospitals, in 
which data were extracted from medical records of 380 outpatients with cancer. Data of 
the first three visits at the outpatient clinic were studied. In 23% of all 987 visits at the 
outpatient clinic pain or absence of pain was registered and in an additional 15% a 
non-specific symptom description was given. Regarding all other visits (62%) pain or 
absence of pain was not documented at all. Pain measurement using a VAS or NRS was 
documented in only one visit. Pain was more often registered in medical records of 
patients with metastasis, as well as urogenital tumours. To conclude, pain in medical 
oncology outpatients is not systematically registered in their medical records. Pain was 
not registered with a VAS or NRS. 
 Registration and assessment of pain in order to monitor pain are essential to evaluate 
and adapt pain treatment over time. Apparently, since 2001 pain registration has not improved. 
Therefore, implementation of recommendations regarding systematic monitoring of pain 
is needed. 
The study described in chapter 4 is based on the results of a cross-sectional case vignette 
survey describing a patient with pancreatic cancer and pain. This survey was sent to all 268 
medical oncologists registered at the Netherlands Association of Internal Medicine. Sixty- 
three of 268 medical oncologists (24%) completed the survey. Adherence to the different 
recommendations of the guideline ranged from 18 to 100%. Confidence for treatment 
choice ranged from 5.6 to 9.5 on a Numeric Rating Scale (0–10). Most of the responding 
oncologists (94%) adhered to prescribing paracetamol as first-line pain treatment, and all 
prescribed a laxative in combination with opioids to prevent constipation. However, only 
24% of the respondents adhered to the guideline when first-line treatment had insufficient 
effect. Additionally, only 35% adhered to the recommendation for insomnia treatment 
providing psychosocial support or using a multidimensional pain questionnaire besides 
pharmacological treatment. Finally, only 18% adhered to the recommendation to perform 
a multidimensional pain assessment when disease worsens and pain increases. To conclude, 
the recommendations of the guideline have been partly adopted in cancer pain practice 
by medical oncologists. Particularly pain assessment is not applied in the recommended 
manner. Therefore, implementation strategies should focus on adequate pain assessment 
in patients with cancer.
In chapter 5, we described the protocol of a cluster randomised controlled trial with three 
hospitals in the intervention and three in the control condition. The intervention included 
training of professionals and IVR with SMS-alerts (MIDAS 4 Cancer Pain) to report pain in 
patients with cancer. The objective was to improve pain reporting by patients and pain 
management by medical oncologists and nurses. This implementation strategy with 
technical tools might encourage patients active involvement in their pain management 
and may enhance the use of the guideline ‘pain in patients with cancer’ for pain management. 
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Samenvatting
In dit proefschrift hebben we bij patiënten met kanker het effect onderzocht van het 
monitoren van pijn met telemedicine op het percentage patiënten met een inadequate 
pijnbehandeling en de actieve betrokkenheid van de patiënt bij zijn eigen pijnbehandel-
ing bediscussieerd. Met telemedicine wordt bedoelt de technologie die gebruikt wordt 
om informatie uit te wisselen tussen patiënt en zorgverlener. Daarnaast worden er in dit 
proefschrift aanbevelingen gedaan voor de klinische praktijk. De doelstelling van dit 
proefschrift is: bewustwording voor de omvang van het probleem en aanbevelingen 
formuleren om pijnmanagement bij patiënten met kanker te verbeteren. 
 Ten eerste, hebben we de pijnprevalentie, pijnintensiteit, de belemmering bij het 
uitvoeren van dagelijkse activiteiten onderzocht en we hebben vastgesteld bij hoeveel 
patiënten de pijnbehandeling adequaat was. Ten tweede, hebben we de pijnregistratie 
van oncologen in medische dossiers bij patiënten met kanker geëvalueerd. Ten derde, zijn 
we met behulp van een casus nagegaan of medisch oncologen de intentie rapporteren 
dat zij deze patiënt zouden behandelen volgens de aanbevelingen van de richtlijn pijn bij 
kanker. Daarnaast, hebben we het effect van het monitoren van pijn met telemedicine 
onderzocht op inadequate pijnbehandeling bij patiënten met kanker. Tenslotte, hebben 
we met behulp van een literatuuronderzoek onderzocht hoe empowerment of gerelateerde 
termen beschreven worden in relatie tot pijnmanagement bij patiënten met kanker. 
In hoofdstuk 1, hebben we de achtergrond van dit proefschrift beschreven met epidemi-
ologische data, definities, het doel van klinische richtlijnen, de theoretische achtergrond, 
de onderbouwing voor het gebruik van IVR-SMS om pijn mee te monitoren en ten slotte 
de opzet van dit proefschrift. 
In hoofdstuk 2,  beschrijven we de resultaten van een onderzoek waaraan 428 patiënten 
met kanker uit de polikliniek deelnamen. De pijnprevalentie en de belemmeringen in het 
uitvoeren van dagelijkse activiteiten zijn onderzocht met de Brief Pain Inventory vragenlijst. 
Of de pijnbehandeling adequaat was is berekend met de Pain Management Index (PMI). 
Meer dan een derde van alle patiënten had pijn (39%). Drieëntachtig patiënten (20% van 
alle patiënten) gaf aan gemiddeld tot ernstige pijn te hebben (NRS 5-10). De pijnbehandel-
ing was inadequaat in meer dan de helft van de patiënten met pijn (62%). De mate waarin 
een patiënt belemmeringen ervaart bij het uitvoeren van dagelijkse activiteiten nam toe 
als de pijnintensiteit ook toe nam. Zelfs 10%-33% van de patiënten met milde pijn gaf aan 
veel belemmering te ervaren bij het uitvoeren van dagelijkse activiteiten. We kunnen 
concluderen dat de pijn behandeling nog steeds een probleem is in de polikliniek bij 
patiënten met kanker. Omdat pijnverlichting bij 86% van de patiënten haalbaar is, blijkt uit 
onze studie dat pijn bij kanker vaak nog niet voldoende behandeld wordt. 
 We recommend focusing on pain treatment given by the professional, on the active 
involvement of the patient, and on the interaction of both. Our model might also be 
useful for other patient groups or specific contexts, especially in symptom management. 
 
In chapter 8, the most important findings and conclusions are discussed. Besides, 
methodological issues are discussed and recommendations for policy makers, clinical 
practice and future research were provided. 
 This thesis adds that adequacy of pain treatment in patients with cancer at the 
outpatient clinic has not improved, partly due to the lack of systematic pain registration 
and proper pain assessment. Today, both healthcare professionals and administrators 
clearly recognize that patient centred care is important. 
 As shown in this thesis pain monitoring with MIDAS 4 Cancer Pain in patients with 
cancer is feasible and it reduced inadequate pain treatment in patients with moderate to 
severe pain. It facilitates systematic pain assessment and registration with a validated pain 
assessment scale and supports caregivers and patients to achieve patient centred care. 
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In hoofdstuk 6, bespreken we de resultaten van een cluster gerandomiseerde 
gecontroleerde studie. Onze doelstelling was onderzoeken wat het effect is van het 
monitoren van pijn bij kanker op afstand met automatische telefoontjes (MIDAS 4 Cancer 
Pain). Acht ziekenhuizen zijn cluster gerandomiseerd. Ziekenhuizen werden toegewezen 
aan de MIDAS 4 Cancer Pain interventie of een pijndagboekje. De primaire uitkomst was 
inadequate pijnbehandeling bij week 12. Secundaire uitkomsten waren pijnintensiteit, 
neuropatische pijn karakteristieken, belemmering in dagelijkse activiteiten, determinanten 
van pijn, kwaliteit van leven, angst, depressie en self-efficacy met betrekking tot het 
communiceren over de pijn. 111 patiënten met kanker en pijn hebben deelgenomen aan 
deze studie. 
Het percentage patiënten met een negatieve PMI (inadequate pijnbehandeling) in de 
MIDAS 4 Cancer Pain groep was niet significant lager dan in the controle groep (16%; 
95%CI -3 tot 35; P=0.12). Pijn gerelateerde belemmering in dagelijkse activiteiten en de 
score voor depressie waren significant lager in de MIDAS 4 Cancer Pain groep. In de 
subgroep van patiënten met matig tot ernstige pijn (NRS 5-10) bij baseline, was het 
percentage van patiënten met een negatieve PMI significant lager in the MIDAS 4 Cancer 
Pain groep dan de controle groep (35%; 95% CI 7 tot 62; p=0.03). De resultaten van de 
subgroep patiënten met matig tot ernstige pijn liet zien dat de interventie significant 
effectiever was in het reduceren van inadequate pijnbehandeling dan de controle. Onze 
resultaten zijn daardoor veelbelovend bij het definiëren van subgroepen voor wie de 
interventie effectief zou zijn. Daarnaast laten onze resultaten positieve effecten zien van 
MIDAS 4 Cancer Pain voor pijn gerelateerde belemmeringen in dagelijkse activiteiten en 
voor depressie.  
Onze  literatuurstudie (integrative review) hebben we in hoofdstuk 7 beschreven. De 
databases PubMed, CINAHL and PsycINFO zijn gebruikt voor deze studie. We evalueerden 
artikelen die empowerment of een gerelateerde term beschreven in relatie tot pijn- 
management bij patiënten met kanker. We analyseerden de term “empowerment” op 
basis van betekenis. Van de 5984 geïdentificeerde artikelen, zijn er 34 geïncludeerd voor 
de analyse. Empowerment is beschreven met de concepten self-efficacy, actieve participatie 
van de patiënt, vergroten van mogelijkheden, en gevoel van controle over het leven. De 
meeste artikelen over pijnmangement focussen op de behandeling geïnduceerd door de 
zorgverlener of de actieve betrokkenheid van de patiënt en niet de combinatie van beide.
 De volgende elementen van empowerment kunnen worden onderscheiden: de rol 
van de patiënt, de rol van de professional, benodigdheden (resources), self-efficacy, actieve 
coping en gedeelde besluitvorming (shared-decision making). Gebaseerd op deze 
resultaten, hebben we een conceptueel model beschreven om de patiënt te empoweren 
bij het onder controle krijgen van de pijn. Dit model zou ook bruikbaar kunnen zijn voor 
andere patiëntgroepen of in een andere context vooral voor symptoommanagement. 
In hoofdstuk 3, beschrijven we de resultaten van een studie in zes Nederlandse zieken- 
huizen, waar we data hebben verzameld uit medische dossiers van 380 patiënten die de 
polikliniek bezoeken. Data van de eerste drie consulten op de polikliniek zijn bekeken. 
Bij 23% van alle 987 consulten op de polikliniek was pijn of de afwezigheid van pijn 
gedocumenteerd en daarnaast is in 15% van de consulten een niet specifieke symptoom 
beschrijving gedocumenteerd (geen klachten, gaat goed). Van alle consulten was in 62% 
pijn of de afwezigheid van pijn niet gedocumenteerd. Een pijnmeting met een VAS of NRS 
was maar in één consult gedocumenteerd. Pijn werd vaker gedocumenteerd door 
medisch oncologen bij patiënten met uitzaaiingen en bij patiënten met urogenitale 
tumoren. We kunnen concluderen dat pijn door medisch oncologen niet systematisch 
gedocumenteerd wordt in medische dossiers en dat pijn niet gedocumenteerd wordt 
met een VAS of NRS.  Het meten en documenteren van pijn is essentieel om te kunnen 
evalueren wat het effect is van de ingestelde behandeling en om op tijd de behandeling 
aan te kunnen passen als dat nodig is.  
 Sinds 2001 is de documentatie van pijn in medische dossier bij patiënten met kanker 
niet verbeterd. Daarom is implementatie van het systematisch monitoren van pijn nodig. 
In hoofdstuk 4 is een cross-sectioneel onderzoek beschreven, waarbij een vragenlijst 
wordt gebruikt met een casus van een patiënt met pancreaskanker en pijn. Deze vragenlijst 
is gestuurd naar alle 268 medisch oncologen die geregistreerd zijn bij de Nederlandse 
internisten vereniging (NIV). Drieënzestig van de 268 oncologen (24%) hebben de vragen- 
lijst ingevuld en teruggestuurd. De intentie dat zij deze patiënt zouden behandelen 
volgens de aanbevelingen van de richtlijn pijn bij kanker varieerde van 18-100% voor 
verschillende aanbevelingen. De meeste respondenten (94%) rapporteerden de intentie 
te handelen volgens de richtlijn door het voorschrijven van paracetamol als eerstelijns 
pijnbehandeling. 
 Vierentwintig procent van de respondenten rapporteerden de intentie te handelen 
volgens de richtlijn bij de vervolgbehandeling die nodig is als de eerstelijns behandeling 
onvoldoende werkt. Ten slotte rapporteerde maar 18% van de oncologen de intentie om 
een multidimensionale pijnmeting uit te voeren bij progressie van de ziekte en toename 
van de pijn. We kunnen concluderen dat de aanbevelingen van de richtlijn deels bekend 
zijn en naar verwachting deels worden gebruikt door oncologen. Vooral de aanbevelingen 
in de richtlijn met betrekking tot het meten van pijn worden niet altijd toegepast. 
In hoofdstuk 5, beschrijven we het protocol van een cluster gerandomiseerde studie met 
drie ziekenhuizen in de controle conditie en drie in de interventie. De interventie bestaat 
uit een training voor oncologen en verpleegkundigen en het monitoren van pijn met 
IVR-SMS bij patiënten met kanker. Deze interventie heeft als doel het rapporteren van pijn 
te verbeteren en het verbeteren van de pijnbehandeling bij patiënten met kanker. 
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